EVIDENCE-BASED HEMATOLOGICAL SOUNDINGS IN ENTREPRENEURIAL DECISIONS

***Colonel Prof (Dr) Jyotirmaya Satpathy***

*Dept of Management and Leadership, Management University of Africa, Nairobi*

***Prof (Dr) Ahalya Hejmadi***

*Dept. of Behavioural Sciences & Psychology, University of Maryland Global Campus, Adelphi, (USA)*

***Prof (Dr) Lidija Weis***

*Ljubljana School of Business, Ljubljana, Slovenia*

# Abstract

*Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) - making is a region of intense study in bio - human science, and cognitive bio - human science. Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) shape lives that emerge from complexly interlinked anthropoid mind and focuses of copious chastisements. Surveys contours renewed queries, vital theoretic and conjectural feasibilities, challenging slants, stimulating outcomes and impudent allusions. Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) ‘impertinence’ toward problematic deciphering is used to represent the business entrepreneurship as facing a set of substitute passages of action from which a optimum preference neurofeedback must be prepared. ‘Design attitude’ toward problem solving shoulders that it is problematic to project a good substitute. But, with technologically advanced propositions, optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) about which substitute to select becomes inconsequential. Commentary intends to explore how optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s ae taken through the Hematological (CBC) path. Purpose of this thesis is to explore how Hematological (CBC) parametric counts absorb cognito - biological evidence, recognises and frames problematic situations, and chooses appropriate responses. Objective is to reflect upon ‘busitagion’ management from principle grounded perception while representing interdisciplinary turf of ‘randomly cerebral’ bereitschaftsprobables. Methodology takes account of an experiment through Hematological (CBC) apparatus to decide optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)al bereitschaftsprobables. Approach is to address amalgamation of examining protocols and strategies underlying approaches within loosely coupled phenomena of unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables embedded in rationale of biology in behavioural models for understanding unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables in optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) circuit. Results indicate that optimum optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s can be arrived at through Hematological (CBC) calculations. Inferences drawn are that tactical - oriented ‘neuro - agent - business entrepreneurship’ decides, create options, address responses to cognito - ‘cognito ‘optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) ‘circuit’ problems and evaluates métiers of ‘circuit’ using cognito - ‘cognito’ medium.*

**Key Words**: *CBC Count, Optimum Preference Neurofeedback, Substitutes grounded Preference Neurofeedback(S) and ‘Cerebral’ Bereitschaftsprobables.*

# Introduction

* 1. Anthropoid organisations are at crossroads (to explain behaviour) with cerebral science (in what way expanses of brain may be pertinent to management and business entrepreneurship behaviour) and business laying a duct (‘cognito’ perception; interrelation between cerebral discipline and optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making) that seems an inconsistent bereitschaftsprobable with unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables. Inquiry is witnessing an ever-increasing aggregate of multilevel research in

organisational studies that assimilates delineated research domains and propositions novel lens for understanding business practice. A recurring phenomenon i.e., disruption, global business arena is plagued with ‘non - orthodox business replicas’ and ‘disruptors. There is a ‘noise’ for a randomly strategy to make techno - innovation (‘technology’ and ‘innovation’) a reality via unconventional strategy. Organisations are voyaging through ‘busitagion’ (‘businesses and ‘contagion’) spells, with reality changing and evolving continuously. Global ‘busitagion’ order shifts have led to ‘Homo - Psychous’ that replaces ‘Homo us’ by reflecting how individual business entrepreneurships are influenced by psychological neuro - agents, biological neuro - agents and dynamics.

* 1. Cerebral science, with cerebral management, has made advances bringing unprecedented insights into Anthropoid brain and Anthropoid (optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making) nature. Making cogent psychosomatic optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s is a management action. Hominids share designed structural sphere and project stimulus in optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) processes. Crevices amongst judiciousness - grounded scrutiny adopt proxies and anthropological comportment in shepherding interactive exploration in optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making. Business entrepreneurships (‘Neuro - agents’) contract high unpredictability, uncertainty, ambiguity, time pressure and emotional stresses. Cognito - management explores optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making by using cognito - tactical monikers (CTM) to probe how brain behaves in circuit of higher cerebral functions. This has transitioned from plotting and charting from behaviourist approach to cerebral confined effects to evolving extrapolative models that focus on processes prior to response. ‘Deciding to Decide’, ‘Preferring to Prefer’, ‘Deciding to Prefer’ and ‘Preferring to Decide’ are four ‘bordered boundaries’ to analyse cerebral - scientific rationale of cognito - biology in unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables.
  2. Business entrepreneurship researchers have been open to new-fangled ways of shepherding research and enthusiastic to reconnoiter how neural themes may link to orthodox business entrepreneurship erudition. Business entrepreneurship research can dive deeper into multidisciplinary space of business entrepreneurship cerebral science. Where are we at in terms of the connection of cerebral science and business entrepreneurship? Where might we go from here to harvest peak worth of organisational cerebral science investigation in business entrepreneurship? These fundamental questions are the focus of this issue. In this research, fostering fresh thinking, CTM techniques explain neural basis of rationale of biology in unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables. This derives inspiration to probe, develop and contribute by transmitting questions in rationale of biology and applications into perspective of unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables in optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making. What typifies notion of causation in sciences of mind and brain? Are dissimilar notions a prerequisite for different experimentation approaches? Are there variances in notions that are explicitly and implicitly presumed? What counts as causal evidence in business entrepreneurship optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) sciences? What role is played by cognito biological and physical protocols in identifying causal claims of business entrepreneurship sciences of mind and brain? Through brain's cabling map, research highlights probable cause - effect linkage between biology and management in explaining how business entrepreneurship deal in judgement dynamics within the spectrum of unbounded ‘scrolling’ as well as ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables. Convective variabilities are pigeonholed by the fact that even though inclusive model of optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) wave packages cultivate in time, trepidations decline at each given point in unbounded province are connected to infinitude.
  3. Contemporary lack of success and effort necessary for validating models are traced to weak theoretical representation of business entrepreneurship optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making in contemporary ‘mosaic. Is there a prerequisite to review present theoretic archetypes? If affirmative, will that transpire with toting to contemporary frame of

understanding or by obliterating some key central constituents? Does optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) management prose entail interdisciplinary philosophies to explain unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables better? Also, have business management theories instigated such disruption? Attempt is to explore nature of causality, ascertain methods to test causal relations, employ pragmatic (cerebral and logical) approach (es) to causal reasoning and establish a relation by using Hematological (CBC) data to depict neural paths in business entrepreneurship optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making. Hybrid ‘randomly mental’ bereitschaftsprobables’ are emerging as substitute to model complex systems under uncertainty. Do we have all the cognito - biological data we need? Are researchers using right models? Is there new analysis (insight) that could be more effective? And, crucially, do we know what we don’t know (incursion of data)?

# Literature Examinations

* 1. Research has advanced to intermittently take store and replicate on how its core theoretical philosophies are emerging to fundamental novelties in business optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making. This calls for seeking answers to some key research questions. Major finding is that tactical - oriented business neuro - agent attempts to decide, create options, address probable responses to unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables in optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) circuit problems via ‘adaptation pathways approach’ to support design of adaptive plan grounded on exploring and evaluating adaptation pathways via CTM mode. Thesis concludes with a number of propositions generated from theoretical ‘mosaic’ and presents directions for future research. Emphasis is upon causality that best fits elucidation?
  2. James A. Barham believed that on one hand, using perception about Anthropoid beings and their nature and explication of lucrative deportment dates back to the origin of the subject of s itself. Implying that all lucrative and remunerative studies are grounded on the turn of brain in a prevailing perception. In order to elucidate the cerebral and neural foundation of resolution, probable to route manifold options and decide on an optimum matrix of action, specifically in business entrepreneurship framework via. Cognito physiological source of numerous behaviours to infer the apparatus behind management undertakings from level of cerebrum science and consequently proposition conforming management trials and stratagems has gained ascendancy. Anthropologically ‘Anthropoid’ beings’ style optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s in a framework of restricted prudence (inadequate evidence, cerebral boundaries of brain besides determinate quantum of time for a optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)), subject to predispositions and clamors that lead to comport sub optimally from what neoclassical s proposes. Behavioural s has been displaying this portent for decades. However, disrupting convergence of cerebral bio - human science, psychology, has constructed a fusion pitch christened ‘Cognito’s (‘cognitomanagement’), which with variable approaches unlike traditional is building, at augmented stride, an integrated rationale on Anthropoid resolution (Laza; 2008).
  3. Business entrepreneurship researchers have been open to new-fangled ways of shepherding research and enthusiastic to reconnoiter how neural themes may link to orthodox business entrepreneurship erudition. Business entrepreneurship research can dive deeper into multidisciplinary space of business entrepreneurship cerebral science. Where are we at in terms of the connection of cerebral science and business entrepreneurship? Where might we go from here to harvest peak worth of organisational cerebral science investigation in business entrepreneurship? These fundamental questions are the focus of this issue. In this thesis, fostering fresh thinking, CTM techniques explain neural basis of rationale of biology in unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables. This derives inspiration to probe, develop and contribute by transmitting questions in rationale of biology and applications into perspective of unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables in optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making. What typifies notion of causation in sciences of brain and cerebrum? Are

dissimilar notions a prerequisite for different experimentation approaches? Are there variances in notions that are explicitly and implicitly presumed? What counts as causal evidence in business entrepreneurship optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) sciences? What role is played by cognitobiological and physical protocols in identifying causal claims of business entrepreneurship sciences of brain and cerebrum? Through cerebrum's cabling map, thesis highlights probable cause - effect linkage between biology and management in explaining how business entrepreneurship deal in judgement dynamics within the spectrum of unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables. Convective variabilities are pigeonholed by the fact that even though inclusive model of optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) wave packages cultivate in time, trepidations decline at each given point in unbounded province are connected to infinitude.

* 1. Contemporary lack of success and effort necessary for validating models are traced to weak theoretical representation of business entrepreneurship optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making in contemporary ‘mosaic. Is there a prerequisite to review present theoretic archetypes? If affirmative, will that transpire with toting to contemporary frame of understanding or by obliterating some key central constituents? Does optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) management prose entail interdisciplinary philosophies to explicate unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables better? Also, have business management theories instigated such disruption? Attempt is to explore nature of causality, ascertain methods to test causal relations employ pragmatic (cerebral and logical) approach (es) to causal reasoning and establish a relation by using Hematological (CBC) data to depict neural paths in business entrepreneurship optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making. Hybrid ‘randomly mental’ bereitschaftsprobables’ are emerging as substitute to model complex systems under uncertainty. Do we have all the information we need? Are researchers using right models? Is there new analysis (insight) that could be more effective? And, crucially, do we know what we don’t know (incursion of data)?
  2. On a contemporary view point, Daniel Kahneman (b. Mar 1934) is of the judgement that results from behaviour of individual neuro - agents lead to optimum preference neurofeedback and substitutes grounded preference neurofeedback(s). The oration rests on the determinants (‘rationality’ as well as ‘instrumental rationality’ are used as postulation of behaviour) of individual optimum preference neurofeedback (methodological individualism) fact. These ‘reference points or ‘frame’ have amalgamated into ‘Thinking: Fast (swift, nimble, mechanized, preprogrammed, recurrent, emotional, stereotypic, insentient, inanimate) and Slow (steady, relaxed, effortful, non-recurrent, logical, calculating, rational, insightful, animate) with reference to optimum preference neurofeedback under uncertainty, quantum cognition, conjoint evaluation, intertemporal optimum preference neurofeedback, complex situations, constraint satisfaction, optimum preference neurofeedback modelling, causal configurations, heuristics and substitutes.
  3. With precipitateness**,** incursion of facts**,** information overload**,** judgements and objectivity, misidentifying the problem, overconfidence in the outcome, not having enough information**,** it is imperative for the ‘optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) maker’ or ‘optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) agent’ i.e. entrepreneurship to take a stand point on conceptual headway and develop next-generation postulates (Gustafsson, et al., 2016; Meredith, 1993). Foremost, professional ‘optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) maker’ or ‘optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) agent’ has grown from physical entity to virtual and digital entity with the transformation redefining fixated boundaries of optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) mechanism. This magnets consideration of management ‘optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) maker’ or ‘optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) agent’ to understand the alteration and plot judgments on phenomenological vicissitudes these agents have undertaken optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) path. Changing spells with growing literature weights and challenges next

generation philosophers to big renewed perceptions to prevailing cognitobiology of resolution viz. explanatory, optimistic, investigational and exploratory outline, long term and continuing studies, group details and specifics, etc. to elucidate business pronouncements better.

* 1. Quantification and qualitative exposition of choosing a substitute is, in part, on account of ‘Matching Law’ (connection that holds between comparative rates of response and comparative rates of underpinning in simultaneous agendas of underpinning). Amalgamation between behavioural and neural science with business entrepreneurship s, neural protocols depict about how cerebrum encodes specific optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) neuro - agents. Are we imminent on the management optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) issues and corresponding optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s with the veracious perspective? This issue has persistently cropped up leading to business entrepreneurship optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) intricacies perfectly perched on business entrepreneurships’ optimum preference neurofeedback behavior. Theoretical exponents’ developed architectures that calibrated pre -disposition of relatively multifarious optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making protocols. This is paving way for lab setting architectures in Cerebrum Plotting and charting (Eye Tracking, Skin Conductance / EDA, MRI, MRI, BOLD, EEG, MEG, ECG, TMS, CT, PET, SNM, BOLD and DCS). ‘cognito’ micro feasibilities of optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) crafting has conservatively acknowledged significant consideration from Loewenstein (2001), Slovic (2002), Tversky and Kahneman (1975), Bechara (2004), Clark (2003), Damasio (1996), Lhermitte (1986), Shallice and Burgess (1991), Ernst (2004), Paulus (2003), Rogers (1999), Clark (2004), Glimcher (2002), Gold and Shadlen (2001), Platt and Glimcher (1999). Maiden in roads were initiated from Bechara (2004) and Damasio (1996). These exceptional arrivals registered cerebrum expanses obligatory for adaptive judgement crafting and provisioned abstract depictions of critical planes of optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) carving (Damasio; 1996).

Perennial and corroborative incursionary incursion of facts, figures, statistics or data has inundated the optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) maker with drifts, inclinations and trends and patterns or template of behaviour that impetuses to reconnoiter prospects to alter and overhaul philosophies to suit contemporary ‘optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)’ needs. The imperious issue is whether there is a prerequisite to review prevailing ‘theoretic models? If in the affirmative, will that come about with toting to standing frame of cognito - biological information or obliterating more or less some vital central protocols? Do ‘optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)’ management transcripts necessitate interdisciplinary schemes to explain ‘optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)’ in a better connotative framework? What then would be the general insinuations of cognito (business entrepreneurship) management? Attention is on ‘Bereitschaftsprobable’ (German) meaning ‘pre-motor probable’ or ‘gameness prospective’.

# Purpose and Objective

* 1. Outcomes and inferences are inescapable part of the pursuits of an anthropoid being, and life every day is a matrix of such resolutions. Conceptual elucidations propound discernible calculations. However, management had no concrete elucidations to some factual queries it could contrive in resolution techniques. Idiosyncratically, investigators are interested in suppositions, philosophies, behaviours and maneuvers to make optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s. Over the past few years, insightful management has divulged cogent and significant remedies to those queries. Investigation and monitoring have guided insightful management to arrive at irrefutable, scientifically backed elucidations, easing inferences; rather than uncorroborated suppositions. Any recapitulation of business entrepreneurship effort would need elucidation of substrates, apparatuses and capricious properties of influence upon cerebral functions. Insightful resolution propositions tools for modeling behaviour. While varied functions are arriving at different indicative

applications and making conclusive headway, the question of how business entrepreneurships map and outline resolutions via intellect support, impacts insightful business entrepreneurship. Some erudite studies assimilate dominions and center on incipient concerns, contemporary deliberations besides continuing insinuations. Business entrepreneurships’ attempt at optimum ‘business’ optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s through orientation and approach - grounded scheming till ‘response threshold’ is stretched. An emerging paradigm is highlighted along with probable causes and matrix that link biology and management in explaining business entrepreneurship ‘accelerations’ dynamics. What are the cogent cerebrum dynamics underlying resolutions?

* 1. Purpose of this thesis explores how brain absorbs cognitobiological information, recognises and frames problematic situations, and chooses appropriate responses. Objective is to reflect upon ‘busitagion’ management from principle - grounded perception while representing interdisciplinary turf of ‘randomly cerebral’ bereitschaftsprobables. With focal point on ‘busitagion’; how do business entrepreneurships choose what action to take? What characteristics of substitutes would aid make business entrepreneurships develop judgement skills? Do business entrepreneurships really have a optimum preference neurofeedback? Research intends to explore an elucidation linked to ‘busitagion’ scenario via unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables. Objective is to reflect upon ‘busitagion’ management from a principle - grounded perspective while representing interdisciplinary turf of ‘Homo - Psychous’ sophistications vis – a – vis unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables. Attempt is to address synthesis of examining psychological protocols and strategies underlying theories and methodological approaches within the loosely coupled phenomena of unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables embedded in macro contexts. Aim is towards awning theoretic contexts and pragmatic methods of rationale of biology in behavioural models for understanding heterogeneity of unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables inner - optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) circuit.
  2. Research has advanced to intermittently take store and replicate on how its core theoretical philosophies are emerging to fundamental novelties in business optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making. This calls for seeking answers to some key research questions. Major finding is that tactical - oriented business neuro - agent attempts to decide, create options, address probable responses to unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables in optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) circuit problems via ‘adaptation pathways approach’ to support design of adaptive plan grounded on exploring and evaluating adaptation pathways via CTM mode. Research concludes with a number of propositions generated from theoretical ‘mosaic’ and presents directions for future research. Emphasis is upon causality that best fits elucidation?
  3. Research endeavours towards rethinking foundations of business entrepreneurship unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables by providing substitute taxonomy for rational optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) problems. Considerations are grounded on critical analysis of relevant literature and cerebral results obtained in an initial pragmatic study. This magnets responsiveness of management philosophers to comprehend renovation and plotting judgements on phenomenological vicissitudes optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making in ‘randomly cerebral’ bereitschaftsprobables in optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) circuit problems have gone through. Such an approach adds depth and richness to theoretical reasoning and improves conversations by providing details concerning how business entrepreneurships operate and behave in an air of unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables.

# Methodologies (Empirical Approximations)

* 1. Empirical methodology approximations include an experiment through Hematological (CBC) apparatus to decide optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)al bereitschaftsprobables. Approach addresses amalgamation of examining protocols and strategies underlying approaches within loosely coupled phenomena of unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables embedded in rationale of biology in behavioural models for understanding unbounded ‘scrolling’ and ‘interpolations’ in ‘randomly cerebral’ bereitschaftsprobables in optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) circuit. In order to have a cognito - peep towards an inquiry into significance of assimilating cognito scientific data transversely with an assortment of plotting and charting architectural protocols. This thesis adopts the Complete Blood Count (CBC) Model. Complete Blood Count was conducted by the use of ‘Hematology Analyzer’ apparatus that estimated cells and assimilated data counts on size and structure. Absorption of hemoglobin was calibrated and indices were designed from red counts. Assistance of a hematology expert was sought for electrical impedance, fluorescent flow cytometry and flow cytometry aspects. CBC methodology was adopted as it aided in assisting decipher increases and / or decreases in blood cell counts.
  2. Satpathy and Mallik (2018), in a study on ‘Hematological Judgement in Business entrepreneurship optimum preference neurofeedback and Substitutes grounded preference neurofeedback(s)’Submitted experimentations in reconnoitering optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making behaviour via Hematological (CBC) perspicacity. Managing a ‘situation reaction test’ (premeditated to experimentation reactions to confront unusual circumstances with alert brain in day- to-day situations**)**, in pragmatic part, an matrix of quantifiable elucidations was managed to 150 subjects (n = 150; n = 80 Male subjects and n = 70 Female subjects). This architecture was favoured due to constituent of elasticity and disparities in reaction to interpolation paraphernalia. This was done to guarantee that subject serves as own mechanism. Blood samples were drawn from each blood cohort. Data have been attuned and corroborated. An inter - correlational evaluation has been shepherded. This assured and warranted unremitting valuation, orientation point valuation and unpredictability in data. Evaluation divulges that blood cohorts do have a character in business entrepreneurship optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) subtleties.

|  |  |  |  |
| --- | --- | --- | --- |
| **TABLE – 1 NORMAL OBSERVATIONS**  **MALE SUBJECTS (Aged: 25 - 40 Years) (ROUNDED - OFF AVERAGE RECORDINGS)** | | | |
| **INVESTIGATION** | **RESULT** | **NORMAL RANGE** | **REMARK** |
| **Blood Sugar Fasting** | **70 mg / dl** | **60 - 100** | **Normal** |
| **Blood Sugar Post**  **- Prandial** | **110 mg / dl** | **< 140** | **Normal** |
| **Blood Sugar Random** | **179 mg / dl** | **< 200** | **Normal** |
| **Urea** | **27 mg / dl** | **15 – 40** | **Normal** |
| **Creatine** | **0.6 mg / dl** | **0.5 – 1.0** | **Normal** |
| **Sodium** | **141 mEq**  **/ L** | **130 - 145** | **Normal** |
| **Potassium** | **3.9 mEq**  **/ L** | **3.5 – 5.0** | **Normal** |
| **Lipid T - Cholesterol** | **138 mg / dl** | **< 200** | **Normal** |
| **Lipid Tri - Glyceride** | **78 mg / dl** | **60 - 150** | **Normal** |
| **Low Density Lipo Protein** | **79 mg / dl** | **60 - 130** | **Normal** |
| **Very Low**  **Density Lipo Protein** | **31 mg / dl** | **00 - 36** | **Normal** |
| **High Density Lipo Protein** | **56 mg / dl** | **40 - 60** | **Normal** |
| **S Bilirubin Total** | **0.9 mg / dl** | **0.1 - 1.2** | **Normal** |
| **S Bilirubin Direct** | **0. 2 mg / dl** | **< 0.3** | **Normal** |
| **S Bilirubin Indirect** | **0.4 mg / dl** | **0.1 – 1.0** | **Normal** |
| **Aspartate Trans Amines (AST)** | **24 IU /**  **L** | **15 - 40** | **Normal** |
| **Alanine Trans Amines (ALT)** | **23 IU /**  **L** | **15 - 40** | **Normal** |
| **Creatine Phosphate K** | **21** | **M : 6 - 37** | **Normal** |
| **CPK - Muscular**  **/ Brain** | **14** | **F : 5 - 27** | **Normal** |
| **GGT** | **12 IU /**  **L** |  |  |
| **T - Protein** | **6.3 g / dl** | **6 - 8** | **Normal** |
| **Albumin** | **3.9 g / dl** | **3.5 - 5.5** | **Normal** |
| **Globulin** | **1.9 g / dl** | **1.7 - 3.2** | **Normal** |
| **A : G Ratio** | **3.9 : 1.9** |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **TABLE – 2 NORMAL OBSERVATIONS**  **MALE SUBJECTS (Aged : 40 - 55 Years) (ROUNDED - OFF AVERAGE RECORDINGS)** | | | |
| **INVESTIGATIO**  **N** | **RESULT** | **NORMA**  **L RANGE** | **REMARK** |
| **Blood Sugar Fasting** | **71 mg / dl** | **60 - 100** | **Normal** |
| **Blood Sugar Post**  **- Prandial** | **87 mg / dl** | **< 140** | **Normal** |
| **Blood Sugar Random** | **113 mg / dl** | **< 200** | **Normal** |
| **Urea** | **19 mg / dl** | **15 – 40** | **Normal** |
| **Creatine** | **0.6 mg / dl** | **0.5 – 1.0** | **Normal** |
| **Sodium** | **141 mEq**  **/ L** | **130 - 145** | **Normal** |
| **Potassium** | **3.7 mEq**  **/ L** | **3.5 – 5.0** | **Normal** |
| **Lipid T - Cholesterol** | **119 mg / dl** | **< 200** | **Normal** |
| **Lipid Tri - Glyceride** | **71 mg / dl** | **60 - 150** | **Normal** |
| **Low Density Lipo Protein** | **79 mg / dl** | **60 - 130** | **Normal** |
| **Very Low**  **Density Lipo Protein** | **24 mg / dl** | **00 - 36** | **Normal** |
| **High Density Lipo Protein** | **48 mg / dl** | **40 - 60** | **Normal** |
| **S Bilirubin Total** | **0.7 mg /**  **dl** | **0.1 - 1.2** | **Normal** |
| **S Bilirubin Direct** | **0.1 mg / dl** | **< 0.3** | **Normal** |
| **S Bilirubin**  **Indirect** | **0.4 mg /**  **dl** | **0.1 – 1.0** | **Normal** |
| **Aspartate Trans Amines (AST)** | **22 IU / L** | **15 - 40** | **Normal** |
| **Alanine Trans**  **Amines (ALT)** | **19 IU / L** | **15 - 40** | **Normal** |
| **Creatine Phosphate K** | **21** | **M : 6 - 37** | **Normal** |
| **CPK - Muscular**  **/ Brain** | **26** | **F : 5 -**  **27** | **Normal** |
| **GGT** | **21 IU / L** |  |  |
| **T - Protein** | **6.7 g / dl** | **6 - 8** | **Normal** |
| **Albumin** | **3.6 g / dl** | **3.5 - 5.5** | **Normal** |
| **Globulin** | **1.2 g / dl** | **1.7 - 3.2** | **Normal** |
| **A : G Ratio** | **3.6: 1.2** |  |  |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TABLE – 3 NORMAL OBSERVATIONS**  **MALE SUBJECTS (Aged : 55 - 70 Years) (ROUNDED - OFF AVERAGE RECORDINGS)** | | | | | |
| **INVESTIGATIO** | | **RESU** |  | | **REMAR** |
| **Blood Fasting** | **Sugar** | **74 mg**  **/ dl** | **60 - 100** | | **Normal** |
| **Blood Sugar Post**  **- Prandial** | | **113**  **mg / dl** | **< 140** | | **Normal** |
| **Blood Random** | **Sugar** | **126**  **mg / dl** | **< 200** | | **Normal** |
| **Urea** | | **25 mg**  **/ dl** | **15 – 40** | | **Normal** |
| **Creatine** | | **0.9 mg**  **/ dl** | **0.5 – 1.0** | | **Normal** |
| **Sodium** | | **137**  **mEq / L** | **130**  **145** | **-** | **Normal** |
| **Potassium** | | **3.9**  **mEq / L** | **3.5 – 5.0** | | **Normal** |
| **Lipid Cholesterol** | **T -** | **124**  **mg / dl** | **< 200** | | **Normal** |
| **Lipid Tri - Glyceride** | | **76 mg**  **/ dl** | **60 - 150** | | **Normal** |
| **Low Density Lipo Protein** | | **79 mg**  **/ dl** | **60 - 130** | | **Normal** |
| **Very Density**  **Protein** | **Low Lipo** | **14 mg / dl** | **00 - 36** | | **Normal** |
| **High Density Lipo Protein** | | **43 mg**  **/ dl** | **40 - 60** | | **Normal** |
| **S Bilirubin Total** | | **0.5 mg**  **/ dl** | **0.1 - 1.2** | | **Normal** |
| **S Bilirubin Direct** | | **0.1 mg**  **/ dl** | **< 0.3** | | **Normal** |
| **S Bilirubin Indirect** | | **0.4 mg**  **/ dl** | **0.1 – 1.0** | | **Normal** |
| **Aspartate Trans Amines (AST)** | | **21 IU /**  **L** | **15 - 40** | | **Normal** |
| **Alanine Trans Amines (ALT)** | | **23 IU /**  **L** | **15 - 40** | | **Normal** |
| **Creatine Phosphate K** | | **8** | **M : 6 - 37** | | **Normal** |
| **CPK - Muscular**  **/ Brain** | | **11** | **F : 5 - 27** | | **Normal** |
| **GGT** | | **21 IU /**  **L** |  | |  |
| **T - Protein** | | **6.4 g / dl** | **6 - 8** | | **Normal** |
| **Albumin** | | **3.7 g / dl** | **3.5 - 5.5** | | **Normal** |
| **Globulin** | | **1.7 g / dl** | **1.7 - 3.2** | | **Normal** |
| **A : G Ratio** | | **3.7 :** |  | |  |

|  |  |  |  |
| --- | --- | --- | --- |
|  | **1.7** |  |  |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TABLE – 4 NORMAL OBSERVATIONS**  **FEMALE SUBJECTS (Aged : 25 - 40 Years) (ROUNDED - OFF AVERAGE RECORDINGS)** | | | | | |
| **INVESTIGATIO** | | **RESU** |  | | **REMAR** |
| **Blood Fasting** | **Sugar** | **76 mg**  **/ dl** | **60 - 100** | | **Normal** |
| **Blood Sugar Post**  **- Prandial** | | **112**  **mg / dl** | **< 140** | | **Normal** |
| **Blood Random** | **Sugar** | **124**  **mg / dl** | **< 200** | | **Normal** |
| **Urea** | | **22 mg**  **/ dl** | **15 – 40** | | **Normal** |
| **Creatine** | | **0.4 mg**  **/ dl** | **0.5 – 1.0** | | **Normal** |
| **Sodium** | | **121**  **mEq / L** | **130**  **145** | **-** | **Normal** |
| **Potassium** | | **3.1**  **mEq / L** | **3.5 – 5.0** | | **Normal** |
| **Lipid**  **Cholesterol** | **T -** | **102**  **mg / dl** | **< 200** | | **Normal** |
| **Lipid Tri - Glyceride** | | **62 mg**  **/ dl** | **60 - 150** | | **Normal** |
| **Low Density**  **Lipo Protein** | | **76 mg**  **/ dl** | **60 - 130** | | **Normal** |
| **Very**  **Density Protein** | **Low Lipo** | **12 mg**  **/ dl** | **00 - 36** | | **Normal** |
| **High Density Lipo Protein** | | **43 mg**  **/ dl** | **40 - 60** | | **Normal** |
| **S Bilirubin Total** | | **0.7 mg**  **/ dl** | **0.1 - 1.2** | | **Normal** |
| **S Bilirubin Direct** | | **0.1 mg**  **/ dl** | **< 0.3** | | **Normal** |
| **S Bilirubin**  **Indirect** | | **0.4 mg**  **/ dl** | **0.1 – 1.0** | | **Normal** |
| **Aspartate Trans Amines (AST)** | | **22 IU /**  **L** | **15 - 40** | | **Normal** |
| **Alanine Trans**  **Amines (ALT)** | | **21 IU /**  **L** | **15 - 40** | | **Normal** |
| **Creatine Phosphate K** | | **7** | **M : 6 - 37** | | **Normal** |
| **CPK - Muscular**  **/ Brain** | | **9** | **F : 5 -**  **27** | | **Normal** |
| **GGT** | | **23 IU /**  **L** |  | |  |
| **T - Protein** | | **7 g / dl** | **6 - 8** | | **Normal** |
| **Albumin** | | **3.1 g / dl** | **3.5 - 5.5** | | **Normal** |
| **Globulin** | | **1.6 g / dl** | **1.7 - 3.2** | | **Normal** |

|  |  |  |  |
| --- | --- | --- | --- |
| **A : G Ratio** | **3.1 :**  **1.6** |  |  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **TABLE – 5 NORMAL OBSERVATIONS**  **FEMALE SUBJECTS (Aged : 40 - 55 Years) (ROUNDED - OFF AVERAGE RECORDINGS)** | | | | | | |
| **INVESTIGATIO** | | **RESULT** | |  | | **REMAR** |
| **Blood Sugar Fasting** | | | **82**  **mg / dl** | **60 - 100** | | **Normal** |
| **Blood Sugar Post - Prandial** | | | **59**  **mg / dl** | **< 140** | | **Normal** |
| **Blood**  **Random** | **Sugar** | | **98**  **mg / dl** | **< 200** | | **Normal** |
| **Urea** | | | **16**  **mg / dl** | **15 – 40** | | **Normal** |
| **Creatine** | | | **0.6**  **mg / dl** | **0.5 – 1.0** | | **Normal** |
| **Sodium** | | | **121**  **mEq / L** | **130**  **145** | **-** | **Normal** |
| **Potassium** | | | **3.2**  **mEq / L** | **3.5 – 5.0** | | **Normal** |
| **Lipid T - Cholesterol** | | | **79**  **mg / dl** | **< 200** | | **Normal** |
| **Lipid Tri - Glyceride** | | | **71**  **mg / dl** | **60 - 150** | | **Normal** |
| **Low Density Lipo Protein** | | | **65**  **mg / dl** | **60 - 130** | | **Normal** |
| **Very Low Density Lipo Protein** | | | **12**  **mg / dl** | **00 - 36** | | **Normal** |
| **High Density Lipo Protein** | | | **41**  **mg / dl** | **40 - 60** | | **Normal** |
| **S Bilirubin Total** | | | **0.4**  **mg / dl** | **0.1 - 1.2** | | **Normal** |
| **S Bilirubin Direct** | | | **0.1**  **mg / dl** | **< 0.3** | | **Normal** |
| **S Bilirubin Indirect** | | | **0.4**  **mg / dl** | **0.1 – 1.0** | | **Normal** |
| **Aspartate Amines (AST)** | **Trans** | | **22 IU**  **/ L** | **15 - 40** | | **Normal** |
| **Alanine Amines (ALT)** | **Trans** | | **21 IU**  **/ L** | **15 - 40** | | **Normal** |
| **Creatine Phosphate**  **K** | | | **7** | **M : 6 - 37** | | **Normal** |
| **CPK - Muscular / Brain** | | | **9** | **F : 5 - 27** | | **Normal** |
| **GGT** | | | **12 IU**  **/ L** |  | |  |
| **T - Protein** | | | **7 g / dl** | **6 - 8** | | **Normal** |
| **Albumin** | | | **3.6 g / dl** | **3.5 - 5.5** | | **Normal** |
| **Globulin** | | | **1.9 g /** | **1.7 - 3.2** | | **Normal** |

|  |  |  |  |
| --- | --- | --- | --- |
|  | **dl** |  |  |
| **A : G Ratio** | **3.6 : 1.9** |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **TABLE – 6 NORMAL OBSERVATIONS**  **FEMALE SUBJECTS (Aged : 55 - 70 Years) (ROUNDED - OFF AVERAGE RECORDINGS)** | | | |
| **INVESTIGATION** | **RESU** |  | **REMAR** |
| **Blood Sugar Fasting** | **47 mg / dl** | **60 - 100** | **Normal** |
| **Blood Sugar Post - Prandial** | **78 mg**  **/ dl** | **< 140** | **Normal** |
| **Blood Sugar Random** | **110**  **mg / dl** | **< 200** | **Normal** |
| **Urea** | **14 mg**  **/ dl** | **15 – 40** | **Normal** |
| **Creatine** | **0.4 mg**  **/ dl** | **0.5 – 1.0** | **Normal** |
| **Sodium** | **115**  **mEq / L** | **130 - 145** | **Normal** |
| **Potassium** | **3.1**  **mEq / L** | **3.5 – 5.0** | **Normal** |
| **Lipid T - Cholesterol** | **78 mg**  **/ dl** | **< 200** | **Normal** |
| **Lipid Tri - Glyceride** | **48 mg**  **/ dl** | **60 - 150** | **Normal** |
| **Low Density Lipo Protein** | **56 mg**  **/ dl** | **60 - 130** | **Normal** |
| **Very Low Density Lipo Protein** | **24 mg / dl** | **00 - 36** | **Normal** |
| **High Density Lipo Protein** | **39 mg**  **/ dl** | **40 - 60** | **Normal** |
| **S Bilirubin Total** | **0.3 mg**  **/ dl** | **0.1 - 1.2** | **Normal** |
| **S Bilirubin Direct** | **0.1 mg**  **/ dl** | **< 0.3** | **Normal** |
| **S Bilirubin Indirect** | **0.3 mg**  **/ dl** | **0.1 – 1.0** | **Normal** |
| **Aspartate Trans Amines (AST)** | **14 IU /**  **L** | **15 - 40** | **Normal** |
| **Alanine Trans Amines (ALT)** | **13 IU /**  **L** | **15 - 40** | **Normal** |
| **Creatine Phosphate K** | **5** | **M : 6 - 37** | **Normal** |
| **CPK - Muscular / Brain** | **4** | **F : 5 - 27** | **Normal** |
| **GGT** | **12 IU /**  **L** |  |  |
| **T - Protein** | **4.9 g / dl** | **6 - 8** | **Normal** |
| **Albumin** | **3.2 g / dl** | **3.5 - 5.5** | **Normal** |

|  |  |  |  |
| --- | --- | --- | --- |
| **Globulin** | **1.6 g / dl** | **1.7 - 3.2** | **Normal** |
| **A : G Ratio** | **3.2 :**  **1.6** |  |  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **TABLE – 7 NORMAL OBSERVATIONS**  **MALE SUBJECTS**  **(COMPARATIVE ROUNDED - OFF AVERAGE RECORDINGS)** | | | | | | |
| **INVESTIGA TION** | | **25 -**  **40** | **40 –**  **55** | **55 -**  **70** | **NOR MAL**  **RANG**  **E** | |
| **RES** | **RES** | **RES** |
| **Blood Fasting** | **Sugar** | **70**  **mg / dl** | **71**  **mg / dl** | **74**  **mg / dl** | **60**  **100** | **-** |
| **Blood Sugar Post - Prandial** | | **110**  **mg / dl** | **87**  **mg / dl** | **113**  **mg / dl** | **< 140** | |
| **Blood Random** | **Sugar** | **179**  **mg / dl** | **113**  **mg / dl** | **126**  **mg / dl** | **< 200** | |
| **Urea** | | **27**  **mg / dl** | **19**  **mg / dl** | **25**  **mg / dl** | **15**  **40** | **–** |
| **Creatine** | | **0.6**  **mg / dl** | **0.6**  **mg / dl** | **0.9**  **mg / dl** | **0.5 – 1.0** | |
| **Sodium** | | **141** | **141** | **137** | **130** | **-** |
| **Potassium** | | **3.9**  **mEq / L** | **3.7**  **mEq / L** | **3.9**  **mEq / L** | **3.5 – 5.0** | |
| **Lipid T - Cholesterol** | | **138**  **mg / dl** | **119**  **mg / dl** | **124**  **mg / dl** | **< 200** | |
| **Lipid Tri - Glyceride** | | **78**  **mg / dl** | **71**  **mg / dl** | **76**  **mg / dl** | **60**  **150** | **-** |
| **Low Density Lipo Protein** | | **79**  **mg / dl** | **79**  **mg / dl** | **79**  **mg / dl** | **60**  **130** | **-** |
| **Very Density**  **Protein** | **Low Lipo** | **31**  **mg / dl** | **24**  **mg / dl** | **14**  **mg / dl** | **00 - 36** | |
| **High Density Lipo Protein** | | **56**  **mg / dl** | **48**  **mg / dl** | **43**  **mg / dl** | **40 - 60** | |
| **S Bilirubin Total** | | **0.9**  **mg / dl** | **mg / dl** | **0.5**  **mg / dl** | **0.1 - 1.2** | |
| **S Bilirubin Direct** | | **0.12**  **mg / dl** | **0.13**  **mg / dl** | **0.1**  **mg / dl** | **< 0.3** | |
| **S Bilirubin Indirect** | | **0.4**  **mg / dl** | **0.4**  **mg / dl** | **0.4**  **mg / dl** | **0.1 – 1.0** | |
| **Aspartate Trans Amines**  **(AST)** | | **24**  **IU / L** | **22**  **IU / L** | **21**  **IU / L** | **15 - 40** | |
| **Alanine Trans Amines (ALT)** | | **23**  **IU / L** | **19**  **IU / L** | **23**  **IU / L** | **15 - 40** | |
| **Creatine**  **Phosphate K** | | **21** | **21** | **8** | **M : 6**  **- 37** | |
| **CPK** | **-** | **14** | **26** | **11** | **F : 5** | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Muscular / Brain** |  |  |  | **- 27** |
| **GGT** | **12**  **IU / L** | **21**  **IU / L** | **21**  **IU / L** |  |
| **T - Protein** | **6.3 g**  **/ dl** | **6.7 g**  **/ dl** | **6.4 g**  **/ dl** | **6 - 8** |
| **Albumin** | **3.9 g**  **/ dl** | **3.6 g**  **/ dl** | **3.7 g**  **/ dl** | **3.5 - 5.5** |
| **Globulin** | **1.9 g**  **/ dl** | **1.2 g**  **/ dl** | **1.7 g**  **/ dl** | **1.7 - 3.2** |
| **A : G Ratio** | **3.9 : 1.9** | **3.6:**  **1.2** | **3.7 : 1.7** |  |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **TABLE – 8 NORMAL OBSERVATIONS**  **FEMALE SUBJECTS**  **(COMPARATIVE ROUNDED - OFF AVERAGE RECORDINGS)** | | | | | | | |
| **INVESTIGATION** | | **25 –**  **40**  **Yea** | | **40 –**  **55**  **Yea** | | **55 –**  **70**  **Year** | **N OR MA L** |
| **RES** | | **RES** | | **RES** |
| **Blood Sugar Fasting** | | **76**  **mg** | **/** | **82**  **mg** | **/** | **78**  **mg / dl** | **60**  **- 100** |
| **Blood Sugar Post - Prandial** | | **112**  **mg dl** | **/** | **59**  **mg dl** | **/** | **110**  **mg / dl** | **< 140** |
| **Blood Random** | **Sugar** | **124**  **mg dl** | **/** | **98**  **mg dl** | **/** | **14**  **mg / dl** | **< 200** |
| **Urea** | | **22**  **mg dl** | **/** | **16**  **mg dl** | **/** | **0.4**  **mg / dl** | **15**  **– 40** |
| **Creatine** | | **0.4**  **mg dl** | **/** | **0.6**  **mg dl** | **/** | **115**  **mEq / L** | **0.5**  **– 1.0** |
| **Sodium** | | **121**  **mEq / L** | | **121**  **mEq / L** | | **3.1**  **mEq / L** | **13**  **0 -**  **145** |
| **Potassium** | | **3.1**  **mEq / L** | | **3.2**  **mEq / L** | | **78**  **mg / dl** | **3.5**  **– 5.0** |
| **Lipid T - Cholesterol** | | **102**  **mg dl** | **/** | **79**  **mg dl** | **/** | **48**  **mg / dl** | **< 200** |
| **Lipid Tri - Glyceride** | | **62**  **mg dl** | **/** | **71**  **mg dl** | **/** | **56**  **mg / dl** | **60**  **- 150** |
| **Low Density Lipo** | | **76** | | **65** | | **24** | **60** |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Protein** | | **mg dl** | **/** | **mg dl** | **/** | **mg / dl** | **- 130** | | |
| **Very Low Density Lipo Protein** | | **12**  **mg dl** | **/** | **12**  **mg dl** | **/** | **39**  **mg / dl** | **00**  **- 36** | | |
| **High Density Lipo Protein** | | **43**  **mg dl** | **/** | **41**  **mg dl** | **/** | **0.3**  **mg / dl** | **40**  **- 60** | | |
| **S Bilirubin Total** | | **0.7**  **mg dl** | **/** | **0.4**  **mg dl** | **/** | **0.1**  **mg / dl** | **0.1**  **- 1.2** | | |
| **S Bilirubin Direct** | | **0.1**  **mg dl** | **/** | **0.1**  **mg dl** | **/** | **0.3**  **mg / dl** | **< 0.3** | | |
| **S Bilirubin Indirect** | | **0.4**  **mg dl** | **/** | **0.4**  **mg dl** | **/** | **14**  **IU / L** | **0.1**  **– 1.0** | | |
| **Aspartate** | **Trans** | **22** | | **22** | | **13** | **15** | | |
| **Amines (AST)** |  | **IU / L** | | **IU / L** | | **IU / L** | **- 40** | | |
| **Alanine** | **Trans** | **21** | | **21** | | **5** | **15** | | |
| **Amines (ALT)** |  | **IU / L** | | **IU / L** | |  | **- 40** | | |
| **Creatine Phosphate** | | **7** | | **7** | | **4** | **M** | | |
| **K** | |  | |  | |  | **: 6 -** | | |
|  | |  | |  | |  | **37** | | |
| **CPK - Muscular /** | | **9** | | **9** | | **12** | **F** | | |
| **Brain** | |  | |  | | **IU / L** | **: 5 -** | | |
|  | |  | |  | |  | **27** | | |
| **GGT** | | **23**  **IU / L** | | **12**  **IU / L** | | **4.9 g**  **/ dl** |  | | |
| **T - Protein** | | **7 g / dl** | | **7 g / dl** | | **3.2 g**  **/ dl** | **8** | **6** | **-** |
| **Albumin** | | **3.1** | | **3.6** | | **1.6 g**  **/ dl** | **3.5** | | |
|  | | **g / dl** | | **g / dl** | | **- 5.5** | | |
| **Globulin** | | **1.6** | | **1.9** | | **3.2 :** | **1.7** | | |
|  | | **g / dl** | | **g / dl** | | **1.6** | **- 3.2** | | |
| **A : G Ratio** | | **3.1 :** | | **3.6 :** | |  | | | |
|  | | **1.6** | | **1.9** | |

|  |  |  |  |
| --- | --- | --- | --- |
| **TABLE – 9 ABNORMAL OBSERVATIONS**  **MALE SUBJECTS (Aged : 25 - 40 Years) (ROUNDED - OFF AVERAGE RECORDINGS)** | | | |
| **INVESTIGATI ON** | **RESU LT** | **NORMA**  **L** | **REMARKS** |
| **Blood Sugar Fasting** | **50**  **mg / dl** | **60 - 100** | **Normal** |
| **Blood Sugar Post**  **- Prandial** | **150**  **mg / dl** | **< 140** | **Normal** |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Blood Sugar Random** | | **199**  **mg / dl** | | | **< 200** | | | **Normal** | |  |
| **Urea** | | **41**  **mg / dl** | | | **15 – 40** | | | **Normal** | |
| **Creatine** | | **0.3**  **mg / dl** | | | **0.5 – 1.0** | | | **Normal** | |
| **Sodium** | | **148**  **mEq / L** | | | **130 - 145** | | | **Normal** | |
| **Potassium** | | **3.1**  **mEq / L** | | | **3.5 – 5.0** | | | **Normal** | |
| **Lipid T - Cholesterol** | | **213**  **mg / dl** | | | **< 200** | | | **Normal** | |
| **Lipid Tri - Glyceride** | | **154**  **mg / dl** | | | **60 - 150** | | | **Normal** | |
| **Low Density Lipo Protein** | | **132**  **mg / dl** | | | **60 - 130** | | | **Normal** | |
| **Very Low**  **Density Lipo Protein** | | **39 mg**  **/ dl** | | | **00 - 36** | | | **Normal** | |
| **High Density Lipo Protein** | | **64 mg**  **/ dl** | | | **40 - 60** | | | **Normal** | |
| **S Bilirubin Total** | | **1.9 mg**  **/ dl** | | | **0.1 - 1.2** | | | **Normal** | |
| **S Bilirubin Direct** | | **0. 8 mg**  **/ dl** | | | **< 0.3** | | | **Normal** | |
| **S Bilirubin Indirect** | | **1.4**  **mg / dl** | | | **0.1 – 1.0** | | | **Normal** | |
| **Aspartate Trans Amines (AST)** | | **44**  **/ L** | | **IU** | **15 - 40** | | | **Normal** | |
| **Alanine Trans Amines (ALT)** | | **43**  **/ L** | | **IU** | **15 - 40** | | | **Normal** | |
| **Creatine Phosphate K** | | **31** | | | **M : 6 - 37** | | | **Normal** | |
| **CPK - Muscular**  **/ Brain** | | **27** | | | **27** | **F** | **: 5 -** | **Normal** | |
| **GGT** | | **12**  **/ L** | | **IU** |  | | |  | |
| **T - Protein** | | **7.3 g / dl** | | | **6 - 8** | | | **Normal** | |
| **Albumin** | | **5.9 g / dl** | | | **3.5 - 5.5** | | | **Normal** | |
| **Globulin** | | **3.9 g / dl** | | | **1.7 - 3.2** | | | **Normal** | |
| **A : G Ratio** | | **3.9 :**  **1.9** | | |  | | |  | |
|  | **TABLE – 10 ABNORMAL OBSERVATIONS**  **MALE SUBJECTS (Aged : 40 - 55 Years) (ROUNDED - OFF AVERAGE RECORDINGS)** | | | | | | | | | |
|  | **INVESTIGATION** | | **RESULT** | | | **NORM** | | | **REMAR** | |

|  |  |  |  |
| --- | --- | --- | --- |
| **Blood Sugar Fasting** | **51 mg / dl** | **60 - 100** | **Abnorma**  **l** |
| **Blood Sugar Post - Prandial** | **107 mg / dl** | **< 140** | **Abnorma**  **l** |
| **Blood Sugar Random** | **213 mg / dl** | **< 200** | **Abnorma**  **l** |
| **Urea** | **49 mg / dl** | **15 – 40** | **Abnorma**  **l** |
| **Creatine** | **1.6 mg / dl** | **0.5 – 1.0** | **Abnorma**  **l** |
| **Sodium** | **147 mEq**  **/ L** | **130 -**  **145** | **Abnorma**  **l** |
| **Potassium** | **5.7 mEq**  **/ L** | **3.5 – 5.0** | **Abnorma**  **l** |
| **Lipid T - Cholesterol** | **219 mg / dl** | **< 200** | **Abnorma**  **l** |
| **Lipid Tri - Glyceride** | **111 mg / dl** | **60 - 150** | **Normal** |
| **Low Density Lipo**  **Protein** | **139 mg /**  **dl** | **60 - 130** | **Abnorma**  **l** |
| **Very Low Density Lipo Protein** | **44 mg / dl** | **00 - 36** | **Abnorma**  **l** |
| **High Density Lipo**  **Protein** | **68 mg /**  **dl** | **40 - 60** | **Abnorma**  **l** |
| **S Bilirubin Total** | **1.7 mg / dl** | **0.1 - 1.2** | **Abnorma**  **l** |
| **S Bilirubin Direct** | **0.4 mg /**  **dl** | **< 0.3** | **Abnorma**  **l** |
| **S Bilirubin Indirect** | **1.4 mg / dl** | **0.1 – 1.0** | **Abnorma**  **l** |
| **Aspartate Trans**  **Amines (AST)** | **42 IU / L** | **15 - 40** | **Abnorma**  **l** |
| **Alanine Trans Amines (ALT)** | **49 IU / L** | **15 - 40** | **Abnorma**  **l** |
| **Creatine Phosphate K** | **41** | **M : 6 -**  **37** | **Abnorma**  **l** |
| **CPK - Muscular / Brain** | **36** | **F : 5 - 27** | **Abnorma**  **l** |
| **GGT** | **21 IU / L** |  | **Abnorma**  **l** |
| **T - Protein** | **6.9 g / dl** | **6 - 8** | **Abnorma**  **l** |
| **Albumin** | **5. 6 g / dl** | **3.5 - 5.5** | **Abnorma**  **l** |
| **Globulin** | **3.2 g / dl** | **1.7 - 3.2** | **Abnorma**  **l** |
| **A : G Ratio** | **3.6: 1.2** |  |  |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **TABLE – 11 ABNORMAL OBSERVATIONS**  **MALE SUBJECTS (Aged : 55 - 70 Years) (ROUNDED - OFF AVERAGE RECORDINGS)** | | | | | | | |
| **INVESTIGATION** | | | **RESU** | **NORM** | | **REMAR** | |
| **Blood**  **Fasting** |  | **Sugar** | **54 mg**  **/ dl** | **60 - 100** | | **l** | **Abnorma** |
| **Blood Sugar Post - Prandial** | | | **153**  **mg / dl** | **< 140** | | **l** | **Abnorma** |
| **Blood**  **Random** |  | **Sugar** | **196**  **mg / dl** | **< 200** | | **l** | **Abnorma** |
| **Urea** | | | **35 mg**  **/ dl** | **15 – 40** | | **Normal** | |
| **Creatine** | | | **1.9 mg**  **/ dl** | **0.5 – 1.0** | | **l** | **Abnorma** |
| **Sodium** | | | **147**  **mEq / L** | **130**  **145** | **-** | **l** | **Abnorma** |
| **Potassium** | | | **5.9**  **mEq / L** | **3.5 – 5.0** | | **l** | **Abnorma** |
| **Lipid Cholesterol** | **T** | **-** | **224**  **mg / dl** | **< 200** | | **l** | **Abnorma** |
| **Lipid**  **Glyceride** | **Tri** | **-** | **156**  **mg / dl** | **60 - 150** | | **l** | **Abnorma** |
| **Low Density Lipo Protein** | | | **139**  **mg / dl** | **60 - 130** | | **l** | **Abnorma** |
| **Very Low Density Lipo Protein** | | | **44 mg / dl** | **00 - 36** | | **l** | **Abnorma** |
| **High Density Lipo Protein** | | | **63 mg**  **/ dl** | **40 - 60** | | **l** | **Abnorma** |
| **S Bilirubin Total** | | | **1.5 mg**  **/ dl** | **0.1 - 1.2** | | **l** | **Abnorma** |
| **S Bilirubin Direct** | | | **0.4 mg**  **/ dl** | **< 0.3** | | **l** | **Abnorma** |
| **S Bilirubin Indirect** | | | **1.4 mg**  **/ dl** | **0.1 – 1.0** | | **l** | **Abnorma** |
| **Aspartate Trans Amines (AST)** | | | **41 IU /**  **L** | **15 - 40** | | **l** | **Abnorma** |
| **Alanine Trans Amines (ALT)** | | | **43 IU /**  **L** | **15 - 40** | | **l** | **Abnorma** |
| **Creatine Phosphate**  **K** | | | **38** | **M : 6 - 37** | | **l** | **Abnorma** |
| **CPK - Muscular / Brain** | | | **31** | **F : 5 - 27** | | **l** | **Abnorma** |
| **GGT** | | | **21 IU /**  **L** |  | | **l** | **Abnorma** |
| **T - Protein** | | | **8.4 g / dl** | **6 - 8** | | **l** | **Abnorma** |
| **Albumin** | | | **5.7 g / dl** | **3.5 - 5.5** | | **l** | **Abnorma** |
| **Globulin** | | | **3.7 g / dl** | **1.7 - 3.2** | | **l** | **Abnorma** |
| **A : G Ratio** | | | **3.7 :** |  | | **Abnorma** | |

|  |  |  |  |
| --- | --- | --- | --- |
|  | **1.7** |  | **l** |

|  |  |  |  |
| --- | --- | --- | --- |
| **TABLE – 12 ABNORMAL OBSERVATIONS**  **FEMALE SUBJECTS (Aged : 25 - 40 Years) (ROUNDED - OFF AVERAGE RECORDINGS)** | | | |
| **INVESTIGATION** | **RESU** | **NORM** | **REMAR** |
| **Blood Sugar Fasting** | **56 mg**  **/ dl** | **60 - 100** | **Abnorma**  **l** |
| **Blood Sugar Post - Prandial** | **132**  **mg / dl** | **< 140** | **Normal** |
| **Blood Sugar Random** | **194**  **mg / dl** | **< 200** | **Normal** |
| **Urea** | **42 mg**  **/ dl** | **15 – 40** | **Abnorma**  **l** |
| **Creatine** | **1.4 mg**  **/ dl** | **0.5 – 1.0** | **Abnorma**  **l** |
| **Sodium** | **151**  **mEq / L** | **130 -**  **145** | **Abnorma**  **l** |
| **Potassium** | **5.1**  **mEq / L** | **3.5 – 5.0** | **Abnorma**  **l** |
| **Lipid T - Cholesterol** | **192**  **mg / dl** | **< 200** | **Normal** |
| **Lipid Tri - Glyceride** | **162**  **mg / dl** | **60 - 150** | **Abnorma**  **l** |
| **Low Density Lipo Protein** | **176**  **mg / dl** | **60 - 130** | **Abnorma**  **l** |
| **Very Low Density Lipo Protein** | **82 mg**  **/ dl** | **00 - 36** | **Abnorma**  **l** |
| **High Density Lipo Protein** | **63 mg**  **/ dl** | **40 - 60** | **Abnorma**  **l** |
| **S Bilirubin Total** | **1.7 mg**  **/ dl** | **0.1 - 1.2** | **Abnorma**  **l** |
| **S Bilirubin Direct** | **1.1 mg**  **/ dl** | **< 0.3** | **Abnorma**  **l** |
| **S Bilirubin Indirect** | **1.4 mg**  **/ dl** | **0.1 – 1.0** | **Abnorma**  **l** |
| **Aspartate Trans Amines (AST)** | **42 IU /**  **L** | **15 - 40** | **Abnorma**  **l** |
| **Alanine Trans Amines (ALT)** | **41 IU /**  **L** | **15 - 40** | **Abnorma**  **l** |
| **Creatine Phosphate**  **K** | **47** | **M : 6 - 37** | **Abnorma**  **l** |
| **CPK - Muscular / Brain** | **28** | **F : 5 - 27** | **Abnorma**  **l** |
| **GGT** | **23 IU /**  **L** |  | **Abnorma**  **l** |
| **T - Protein** | **9 g / dl** | **6 - 8** | **Abnorma**  **l** |
| **Albumin** | **5.1 g / dl** | **3.5 - 5.5** | **Normal** |
| **Globulin** | **3.6 g / dl** | **1.7 - 3.2** | **Abnorma**  **l** |
| **A : G Ratio** | **3.1 :** |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
|  | **1.6** |  |  |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **TABLE – 13 ABNORMAL OBSERVATIONS**  **FEMALE SUBJECTS (Aged : 40 - 55 Years) (ROUNDED - OFF AVERAGE RECORDINGS)** | | | | | | | |
| **INVESTIGATIO** | | **RESULT** | | **NORM** | | **REMAR** | |
| **Blood Sugar Fasting** | | | **52**  **mg / dl** | **60 - 100** | | **l** | **Abnorma** |
| **Blood Sugar Post - Prandial** | | | **159**  **mg / dl** | **< 140** | | **l** | **Abnorma** |
| **Blood Random** | **Sugar** | | **198**  **mg / dl** | **< 200** | | **Normal** | |
| **Urea** | | | **56**  **mg / dl** | **15 – 40** | | **l** | **Abnorma** |
| **Creatine** | | | **1.6**  **mg / dl** | **0.5 – 1.0** | | **l** | **Abnorma** |
| **Sodium** | | | **151**  **mEq / L** | **130**  **145** | **-** | **l** | **Abnorma** |
| **Potassium** | | | **5.2**  **mEq / L** | **3.5 – 5.0** | | **l** | **Abnorma** |
| **Lipid T - Cholesterol** | | | **179**  **mg / dl** | **< 200** | | **Normal** | |
| **Lipid Tri - Glyceride** | | | **171**  **mg / dl** | **60 - 150** | | **l** | **Abnorma** |
| **Low Density Lipo Protein** | | | **165**  **mg / dl** | **60 - 130** | | **l** | **Abnorma** |
| **Very Low Density Lipo Protein** | | | **42**  **mg / dl** | **00 - 36** | | **l** | **Abnorma** |
| **High Density Lipo Protein** | | | **51**  **mg / dl** | **40 - 60** | | **Normal** | |
| **S Bilirubin Total** | | | **1.4**  **mg / dl** | **0.1 - 1.2** | | **l** | **Abnorma** |
| **S Bilirubin Direct** | | | **0.4**  **mg / dl** | **< 0.3** | | **l** | **Abnorma** |
| **S Bilirubin Indirect** | | | **1.4**  **mg / dl** | **0.1 – 1.0** | | **l** | **Abnorma** |
| **Aspartate Amines (AST)** | **Trans** | | **42 IU**  **/ L** | **15 - 40** | | **l** | **Abnorma** |
| **Alanine Amines (ALT)** | **Trans** | | **41 IU**  **/ L** | **15 - 40** | | **l** | **Abnorma** |
| **Creatine Phosphate**  **K** | | | **47** | **M : 6 - 37** | | **l** | **Abnorma** |
| **CPK - Muscular / Brain** | | | **29** | **F : 5 - 27** | | **l** | **Abnorma** |
| **GGT** | | | **12 IU**  **/ L** |  | | **l** | **Abnorma** |
| **T - Protein** | | | **9 g / dl** | **6 - 8** | | **l** | **Abnorma** |
| **Albumin** | | | **5.6 g / dl** | **3.5 - 5.5** | | **l** | **Abnorma** |
| **Globulin** | | | **3.9 g / dl** | **1.7 - 3.2** | | **l** | **Abnorma** |
| **A : G Ratio** | | | **3.6 :** |  | |  | |

|  |  |  |  |
| --- | --- | --- | --- |
|  | **1.9** |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **TABLE – 14 ABNORMAL OBSERVATIONS**  **FEMALE SUBJECTS (Aged : 55 - 70 Years) (ROUNDED - OFF AVERAGE RECORDINGS)** | | | |
| **INVESTIGATION** | **RESU** | **NORMA** | **REMAR** |
| **Blood Sugar Fasting** | **47 mg / dl** | **60 - 100** | **Abnorma**  **l** |
| **Blood Sugar Post - Prandial** | **178**  **mg / dl** | **< 140** | **Abnorma**  **l** |
| **Blood Sugar Random** | **190**  **mg / dl** | **< 200** | **Normal** |
| **Urea** | **44 mg**  **/ dl** | **15 – 40** | **Abnorma**  **l** |
| **Creatine** | **1.4 mg**  **/ dl** | **0.5 – 1.0** | **Abnorma**  **l** |
| **Sodium** | **145**  **mEq / L** | **130 - 145** | **Normal** |
| **Potassium** | **5.1**  **mEq / L** | **3.5 – 5.0** | **Abnorma**  **l** |
| **Lipid T - Cholesterol** | **178**  **mg / dl** | **< 200** | **Normal** |
| **Lipid Tri - Glyceride** | **148**  **mg / dl** | **60 - 150** | **Normal** |
| **Low Density Lipo Protein** | **156**  **mg / dl** | **60 - 130** | **Abnorma**  **l** |
| **Very Low Density**  **Lipo Protein** | **34 mg /**  **dl** | **00 - 36** | **Abnorma**  **l** |
| **High Density Lipo Protein** | **69 mg**  **/ dl** | **40 - 60** | **Abnorma**  **l** |
| **S Bilirubin Total** | **1.3 mg**  **/ dl** | **0.1 - 1.2** | **Abnorma**  **l** |
| **S Bilirubin Direct** | **3.1 mg**  **/ dl** | **< 0.3** | **Abnorma**  **l** |
| **S Bilirubin Indirect** | **2.3 mg**  **/ dl** | **0.1 – 1.0** | **Abnorma**  **l** |
| **Aspartate Trans Amines (AST)** | **44 IU /**  **L** | **15 - 40** | **Abnorma**  **l** |
| **Alanine Trans Amines**  **(ALT)** | **43 IU /**  **L** | **15 - 40** | **Abnorma**  **l** |
| **Creatine Phosphate K** | **45** | **M : 6 - 37** | **Abnorma**  **l** |
| **CPK - Muscular /**  **Brain** | **34** | **F : 5 -**  **27** | **Abnorma**  **l** |
| **GGT** | **12 IU /**  **L** |  |  |
| **T - Protein** | **8.9 g /**  **dl** | **6 - 8** | **Abnorma**  **l** |
| **Albumin** | **5.2 g / dl** | **3.5 - 5.5** | **Normal** |
| **Globulin** | **3.6 g /**  **dl** | **1.7 - 3.2** | **Normal** |
| **A : G Ratio** | **3.2 :** |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
|  | **1.6** |  |  |

# CUMULATIVE DATA: ABNORMAL OBSERVATIONS

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **TABLE – 15 ABNORMAL OBSERVATIONS**  **MALE SUBJECTS**  **(COMPARATIVE ROUNDED - OFF AVERAGE RECORDINGS)** | | | | | | |
| **INVESTIGA TION** | | **25 -**  **40**  **Year** | **40 –**  **55**  **Year** | **55 -**  **70**  **Year** | **NOR MAL**  **RANG**  **E** | |
| **RES** | **RES** | **RES** |
| **Blood**  **Fasting** | **Sugar** | **50**  **mg / dl** | **51**  **mg / dl** | **54**  **mg / dl** | **60**  **100** | **-** |
| **Blood Sugar Post - Prandial** | | **150**  **mg / dl** | **107**  **mg / dl** | **153**  **mg / dl** | **< 140** | |
| **Blood**  **Random** | **Sugar** | **199**  **mg / dl** | **213**  **mg / dl** | **196**  **mg / dl** | **< 200** | |
| **Urea** | | **41**  **mg / dl** | **49**  **mg / dl** | **35**  **mg / dl** | **15**  **40** | **–** |
| **Creatine** | | **0.3**  **mg / dl** | **1.6**  **mg / dl** | **1.9**  **mg / dl** | **0.5 – 1.0** | |
| **Sodium** | | **148** | **147** | **147** | **130** | **-** |
| **Potassium** | | **3.1**  **mEq / L** | **5.7**  **mEq / L** | **5.9**  **mEq / L** | **3.5 – 5.0** | |
| **Lipid T - Cholesterol** | | **213**  **mg / dl** | **219**  **mg / dl** | **224**  **mg / dl** | **< 200** | |
| **Lipid Tri -**  **Glyceride** | | **154**  **mg / dl** | **111**  **mg / dl** | **156**  **mg / dl** | **60**  **150** | **-** |
| **Low Density Lipo Protein** | | **132**  **mg / dl** | **139**  **mg / dl** | **139**  **mg / dl** | **60**  **130** | **-** |
| **Very Density Protein** | **Low Lipo** | **39**  **mg / dl** | **44**  **mg / dl** | **44**  **mg / dl** | **00 - 36** | |
| **High Density**  **Lipo Protein** | | **64**  **mg / dl** | **68**  **mg / dl** | **63**  **mg / dl** | **40 - 60** | |
| **S Bilirubin Total** | | **1.9**  **mg / dl** | **1.7**  **mg / dl** | **1.5**  **mg / dl** | **0.1 - 1.2** | |
| **S Bilirubin**  **Direct** | | **0. 8**  **mg / dl** | **0.4**  **mg / dl** | **0.4**  **mg / dl** | **< 0.3** | |
| **S Bilirubin Indirect** | | **1.4**  **mg / dl** | **1.4**  **mg / dl** | **1.4**  **mg / dl** | **0.1 – 1.0** | |
| **Aspartate**  **Trans Amines (AST)** | | **44**  **IU / L** | **42**  **IU / L** | **41**  **IU / L** | **15 - 40** | |
| **Alanine Trans Amines (ALT)** | | **43**  **IU / L** | **49**  **IU / L** | **43**  **IU / L** | **15 - 40** | |
| **Creatine Phosphate K** | | **31** | **41** | **38** | **M : 6**  **- 37** | |
| **CPK**  **Muscular Brain** | **-**  **/** | **27** | **36** | **31** | **F : 5**  **- 27** | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **GGT** | **12**  **IU / L** | **21**  **IU / L** | **21**  **IU / L** |  |
| **T - Protein** | **7.3 g**  **/ dl** | **6.9 g**  **/ dl** | **8.4 g**  **/ dl** | **6 - 8** |
| **Albumin** | **5.9 g**  **/ dl** | **5. 6**  **g / dl** | **5.7 g**  **/ dl** | **3.5 - 5.5** |
| **Globulin** | **3.9 g**  **/ dl** | **3.2 g**  **/ dl** | **3.7 g**  **/ dl** | **1.7 - 3.2** |
| **A : G Ratio** | **3.9 : 1.9** | **3.6:**  **1.2** | **3.7 : 1.7** |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **TABLE – 16 ABNORMAL OBSERVATIONS**  **FEMALE SUBJECTS**  **(COMPARATIVE ROUNDED - OFF AVERAGE RECORDINGS)** | | | | |
| **INVESTIGATIO**  **N** | **25 –**  **40** | **40 – 55**  **Years** | **55 –**  **70** | **N OR**  **MA L** |
| **RES ULT** | **RESUL**  **T** | **RES ULT** |
| **Blood Sugar**  **Fasting** | **56**  **mg /** | **52 mg /**  **dl** | **47**  **mg /** | **60**  **- 100** |
| **Blood Sugar Post**  **- Prandial** | **132**  **mg / dl** | **159 mg**  **/ dl** | **178**  **mg / dl** | **< 140** |
| **Blood Sugar Random** | **194**  **mg / dl** | **198 mg**  **/ dl** | **190**  **mg / dl** | **< 200** |
| **Urea** | **42**  **mg / dl** | **56 mg / dl** | **44**  **mg / dl** | **15**  **– 40** |
| **Creatine** | **1.4**  **mg / dl** | **1.6 mg**  **/ dl** | **1.4**  **mg / dl** | **0.5**  **– 1.0** |
| **Sodium** | **151**  **mEq / L** | **151**  **mEq / L** | **145**  **mEq / L** | **13**  **0 -**  **145** |
| **Potassium** | **5.1**  **mEq / L** | **5.2**  **mEq / L** | **5.1**  **mEq / L** | **3.5**  **– 5.0** |
| **Lipid T - Cholesterol** | **192**  **mg / dl** | **179 mg**  **/ dl** | **178**  **mg / dl** | **< 200** |
| **Lipid Tri - Glyceride** | **162**  **mg / dl** | **171 mg**  **/ dl** | **148**  **mg / dl** | **60**  **- 150** |
| **Low Density Lipo Protein** | **176**  **mg / dl** | **165 mg**  **/ dl** | **156**  **mg / dl** | **60**  **- 130** |
| **Very Low Density Lipo Protein** | **82**  **mg / dl** | **42 mg / dl** | **34**  **mg / dl** | **00**  **- 36** |
| **High Density** | **63** | **51 mg /** | **69** | **40** |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Lipo Protein** | **mg / dl** | **dl** | **mg / dl** | **- 60** |
| **S Bilirubin Total** | **1.7**  **mg / dl** | **1.4 mg**  **/ dl** | **1.3**  **mg / dl** | **0.1**  **- 1.2** |
| **S Bilirubin Direct** | **1.1**  **mg / dl** | **0.4 mg**  **/ dl** | **3.1**  **mg / dl** | **< 0.3** |
| **S Bilirubin Indirect** | **1.4**  **mg / dl** | **1.4 mg**  **/ dl** | **2.3**  **mg / dl** | **0.1**  **– 1.0** |
| **Aspartate Trans Amines (AST)** | **42**  **IU / L** | **42 IU /**  **L** | **44**  **IU / L** | **15**  **- 40** |
| **Alanine Trans Amines (ALT)** | **41**  **IU / L** | **41 IU /**  **L** | **43**  **IU / L** | **15**  **- 40** |
| **Creatine Phosphate K** | **47** | **47** | **45** | **M**  **: 6 -**  **37** |
| **CPK - Muscular / Brain** | **28** | **29** | **34** | **F**  **: 5 -**  **27** |
| **GGT** | **23**  **IU / L** | **12 IU /**  **L** | **12**  **IU / L** |  |
| **T - Protein** | **9 g / dl** | **9 g / dl** | **8.9 g**  **/ dl** | **6 -**  **8** |
| **Albumin** | **5.1**  **g / dl** | **5.6 g / dl** | **5.2 g**  **/ dl** | **3.5**  **- 5.5** |
| **Globulin** | **3.6**  **g / dl** | **3.9 g / dl** | **3.6 g**  **/ dl** | **1.7**  **- 3.2** |
| **A : G Ratio** | **3.1 :**  **1.6** | **3.6 : 1.9** |  | |

1. **ANALYSIS AND DISCUSSIONS**

# GET

FILE='C:\Users\Ritika.DESKTOP-730O9R4\Desktop\phd data final\JS SIR DATA.sa v'. DATASET NAME DataSet1 WINDOW=FRONT. T-TEST GROUPS=Gender(1 2)

/MISSING=ANALYSIS

/VARIABLES=BSF BSP BSR UREA CREATINE SODIUM POTASSIUM LTC LTG LDLP VLDLP HD LP SBT SBD SBI AST ALT CPK CPKMB GGT TP ALBUMIN GLOBULIN AGRATIO

/CRITERIA=CI(.95).

# T-Test

[DataSet1] C:\Users\Ritika.DESKTOP-730O9R4\Desktop\phd data final\JS SIR DATA

.sav

# Group Statistics

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Gender | N | M  e a n | St d. Dev iati  on | St  d. Erro r  Mea n |
| Blood Sugar Fasting  Ma  le | 6 | 6  1  . 6  7 | 1  1.11  2 | 4.  536 |
| Female | 6 | 6  0  . 0  0 | 1  5.21  8 | 6.  213 |
| Blood Sugar Post -  Ma  le  Prandial  Fe  male | 6  6 | 1  2  0  . 0  0 | 2  6.06  1  4  5.99  4 | 10  .640  18  .777 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | 1  1  9  . 6  7 |  |  |
| Blood Sugar Random  Ma  le | 6 | 1  7  1  . 0  0 | 4  1.53  6 | 16  .957 |
| Female | 6 | 1  5  2  . 3  3 | 4  6.44  9 | 18  .963 |
| Urea  Ma  le | 6 | 3  2  . 6  7 | 1  1.13  0 | 4.  544 |
| Female | 6 | 3  2  . 3  3 | 1  7.31  7 | 7.  069 |
| Creatine  Ma  le | 6 | .  9  8  3  3 | .6  306  1 | .2  574  4 |
| Female | 6 | .  9  6  6  7 | .5  573  7 | .2  275  5 |
| Sodium  Ma  le | 6 | 1  4  3  . 5  0 | 4.  461 | 1.  821 |
| Female | 6 | 1  3  4  . | 1  6.72  1 | 6.  826 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | 0  0 |  |  |
| Potassium  Ma  le | 6 | 4  . 3  6  6  7 | 1.  150  07 | .4  695  2 |
| Female | 6 | 4  . 1  3  3  3 | 1.  096  66 | .4  477  1 |
| Lipid T - Cholesterol  Ma  le | 6 | 1  6  2  . 8  3 | 6  3.30  7 | 25  .845 |
| Female | 6 | 1  3  4  . 6  7 | 5  3.86  5 | 21  .990 |
| Lipid Tri - Glyceride  Ma  le | 6 | 1  0  7  . 8  3 | 3  9.14  8 | 15  .982 |
| Female | 6 | 1  1  0  . 3  3 | 5  5.74  5 | 22  .758 |
| Low Density Lipo Protein  Ma  le | 6 | 9  9  . 8  3 | 4  4.06  5 | 17  .990 |
| Female | 6 | 1  1  5  . 6 | 5  5.50  0 | 22  .658 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | 7 |  |  |
| Very Low Density Lipo  Ma  le  Protein  Fe  male | 6  6 | 3  2  . 6  7  3  4  . 3  3 | 1  2.02  8  2  6.21  2 | 4.  910  10  .701 |
| High Density Lipo Protein  Ma  le | 6 | 5  7  . 0  0 | 9.  839 | 4.  017 |
| Female | 6 | 5  1  . 0  0 | 1  2.45  8 | 5.  086 |

**Group Statistics**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Gender | | N | M  e a n | St  d. Dev iati  on | St  d. Erro r Mea  n |
| S Bilirubin | M  a l e | 6 | 1 | .5 | .2 |
| Total |  | . | 761 | 352 |
|  |  | 2 | 9 | 3 |
|  |  | 0 |  |  |
|  |  | 0 |  |  |
|  |  | 0 |  |  |
|  | F  e m a  l e | 6 | . | .5 | .2 |
|  | 9 | 785 | 361 |
|  | 6 | 0 | 7 |
|  | 6 |  |  |
|  | 7 |  |  |
| S Bilirubin | M  a l e | 6 | . | .2 | .1 |
| Direct |  | 3 | 658 | 085 |
|  |  | 3 | 3 | 3 |
|  |  | 3 |  |  |
|  |  | 3 |  |  |
|  | F  e m a l  e | 6 | . | 1. | .4 |
|  | 8 | 183 | 833 |
|  | 1 | 92 | 3 |
|  | 6 |  |  |
|  | 7 |  |  |
| S Bilirubin | M  a l e | 6 | . | .5 | .2 |
| Indirect |  | 9 | 477 | 236 |
|  |  | 0 | 2 | 1 |
|  |  | 0 |  |  |
|  |  | 0 |  |  |
|  | F  e m a l  e | 6 | 1 | .8 | .3 |
|  | . | 016 | 272 |
|  | 0 | 6 | 8 |
|  | 3 |  |  |
|  | 3 |  |  |
|  | 3 |  |  |
| Aspartate Trans Amines | M  a l e | 6 | 3  2 | 1  1.03 | 4.  507 |
|  |  | . | 9 |  |
|  |  | 3 |  |  |
|  |  | 3 |  |  |
| (AST) | F | 6 | 3 | 1 | 5. |

**Group Statistics**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| e | |  | 1 | 3.13 | 360 |
| m | | . | 0 |  |
| a | | 0 |  |  |
| l | | 0 |  |  |
| e | |  |  |  |
| Alanine Trans Amines | M  a l e | 6 | 3  3 | 1  3.04 | 5.  327 |
|  |  | . | 9 |  |
|  |  | 3 |  |  |
|  |  | 3 |  |  |
| (ALT) | F  e m a l  e | 6 | 3 | 1 | 5. |
|  |  | 0 | 3.13 | 360 |
|  |  | . | 0 |  |
|  |  | 0 |  |  |
|  |  | 0 |  |  |
| Creatine | M  a l e | 6 | 2 | 1 | 5. |
| Phosphate K |  | 6 | 2.37 | 051 |
|  |  | . | 2 |  |
|  |  | 6 |  |  |
|  |  | 7 |  |  |
|  | F  e m a l  e | 6 | 2 | 2 | 8. |
|  | 6 | 1.93 | 954 |
|  | . | 3 |  |
|  | 3 |  |  |
|  | 3 |  |  |
| CPK - | M  a l e | 6 | 2 | 1 | 5. |
| Muscular / |  | 2 | 2.81 | 233 |
| Brain |  | . | 8 |  |
|  |  | 5 |  |  |
|  |  | 0 |  |  |
|  | F  e m a l  e | 6 | 1 | 1 | 5. |
|  | 8 | 2.89 | 263 |
|  | . | 1 |  |
|  | 8 |  |  |
|  | 3 |  |  |
| GGT | M  a l e | 6 | 1 | 4. | 1. |
|  |  | 8 | 648 | 897 |
|  |  | . |  |  |
|  |  | 0 |  |  |
|  |  | 0 |  |  |
|  | F  e m a | 6 | 1 | 5. | 2. |
|  | 5 | 680 | 319 |
|  | . |  |  |
|  | 6 |  |  |

**Group Statistics**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| l  e | |  | 7 |  |  |
| T - Protein | M  a l e | 6 | 7 | .7 | .3 |
|  |  | . | 746 | 162 |
|  |  | 0 | 0 | 3 |
|  |  | 0 |  |  |
|  |  | 0 |  |  |
|  |  | 0 |  |  |
|  | F  e m a  l e | 6 | 7 | 1. | .6 |
|  | . | 650 | 736 |
|  | 6 | 05 | 3 |
|  | 3 |  |  |
|  | 3 |  |  |
|  | 3 |  |  |
| Albumin | M  a l e | 6 | 4 | 1. | .4 |
|  |  | . | 103 | 506 |
|  |  | 7 | 93 | 8 |
|  |  | 3 |  |  |
|  |  | 3 |  |  |
|  |  | 3 |  |  |
|  | F  e m a  l e | 6 | 4 | 1. | .4 |
|  | . | 120 | 575 |
|  | 3 | 71 | 3 |
|  | 0 |  |  |
|  | 0 |  |  |
|  | 0 |  |  |
| Globulin | M  a l e | 6 | 2 | 1. | .4 |
|  |  | . | 141 | 661 |
|  |  | 6 | 93 | 9 |
|  |  | 0 |  |  |
|  |  | 0 |  |  |
|  |  | 0 |  |  |
|  | F  e m a  l e | 6 | 2 | 1. | .4 |
|  | . | 106 | 516 |
|  | 7 | 35 | 6 |
|  | 0 |  |  |
|  | 0 |  |  |
|  | 0 |  |  |
| A : G Ratio | M  a  l e | 6 | . | .0 | .0 |
|  |  | 0  0 | 00a | 00 |
|  | F  e m a  l | 6 | . | .0 | .0 |
|  | 0  0 | 00a | 00 |

**Group Statistics**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| e |  |  |  |  |

a. t cannot be computed because the standard deviations of both groups are 0.

**Independent Samples Test**

Levene's Test for Equality of Variances t-test for Equality of

Blood Sugar Fasting Equal variances

F ~~S~~   ~~t~~

assumed

i .

1 g 3

. . 4

0 0

0

3

.217

.217

|  |  |  |  |
| --- | --- | --- | --- |
| Blood Sugar | Equal variances not assumed  Equal | 2  . | 1 |
| Post - | variances | 2 | 6 |
| Prandial | assumed | 5 | 4 |
| Blood Sugar Ra assumed  Equal variances Urea  assumed  Equal variances Creatine  assumed  Equal variances Sodium | Equal variances not assumed  ndom Equal variances  not assumed  Equal variances  not assumed  Equal variances  not assumed  Equal variances | 8  E  q u a l  v a r i a n c  e | e d  i p i d  T  r i  - |

. .015

.015

assumed

Equal variances not assumed Potassium Equal variances

assumed

Equal variances not assumed

Lipid T - Cholesterol Equal variances assumed

Equal variances

~~L~~ assumed

Equal variances not assumed

Low Density Lipo

Protein Eq

Equal

s G variances

l not

n y assumed

o c

t e

r

a i

s d

s e

u

m

.839 **ent Samples Test** . 3

**Independ**

8

1

3.821

.

.008 0

7

9

63.048

.

9

3

.052 1

.924 .

0

0

0

4.932

.

8

2.640 2

5

.734

.734

.

1 .040

3

|  |  |
| --- | --- |
| 5 | .040 |
|  | .049 |
|  | .049 |
|  | 1.345 |
|  | 1.345 |
|  | .360 |
|  | .360 |
|  | .830 |
|  | .830 |
|  | -.090 |
|  | -.090 |
|  | -.547 |
|  | -.547 |

.

3

5

9

.

0

5

1

**Independent Samples Test**

t-test for Equality of Means

Blood Sugar Fasting Equal variances assumed

d) 10 .8

df Sig. (2-taile

Mean Difference 1.667 33

Blood Sugar Post - Prandial

Equal 9 .

variances not . 8

assumed 1 3

Equal 5 3

variances 1

assumed .

1 9

Equal 0 8

variances not 8

assumed 7

. .

9 9

1 8

1 8

1.667

.333

.333

Blood Sugar Random Equal variances assumed

Equal variances not assumed

L a variances not

i l assumed

p Low

i v Density Lipo

Urea Equal variances

d a Protein Equal

assumed

Equal variances not assumed Creatine Equal variances

assumed

Equal variances not assumed

Sodium Equal variances assumed

Equal variances not assumed Potassium Equal variances

assumed

Equal variances not assumed

Lipid T - Cholesterol Equal variances assumed

Equal variances not assumed

r

T i Equal

r a variances not

i n assumed c

- e

s

G

l a

y s

c s

e u

r m

i e

d d

e

E

E q

q u

u a

l

**Indepe**1**n**0**dent Samples Te** .

**st**

4 .

8 4

9.878 0 2

6

10 .

4 .

8.529 8 4

0 2

10 6

.

9.851 9 .

6 9

10 9 3

0

5.708 .

9 .

10 6 9

9 3

9.977 0

.

10 9 .

6 5

9.750 2 9

6

10 .

9 .

8.967 6 5

2 9

10 7

.

9.511 2

0

8

18.667

18.667

.333

.333

.01667

.01667

9.500

9.500

.23333

.23333

28.167

28.167

-2.500

-2.500

-15.833

-15.833

.

2

3

0

.

7

2

7

.

7

2

7

**Independent Samples Test**

t-test for Equality of Means 95% Confidence Interval of the

Blood Sugar Fasting Equal variances assumed

S

td. Err or Dif fer enc e

Difference Lower Upper

-15.474 18.807

7

.69

3

Blood Sugar Post - Prandial

Equal variances not assumed

Equal variances assumed

Equal variances not assumed

7 -

. 1 5

6 5

9 .

3 6 1

9

2 2

1 9

. -

5 4

8 7

2 .

7

2 5

1 4

.

5 -

8 4

2 9

. 5

3

3

19.02

48.42

50.19

Blood Sugar Random Equal variances assumed

Equal variances not assumed

Urea Equal variances assumed

Equal variances not assumed

C E ances

r q assumed

e u

a a Equal

t l variances

i v not

n a assumed

e r Sodiu i

m Equal variances

**Independ**

assumed

Equal variances not assumed Potassium Equal variances

assumed

Equal variances not assumed

Lipid T - Cholesterol Equal variances assumed

Equal variances not assumed

Lipid Tri - Glyceride Equal variances assumed

Equal variances not assumed

Low Density Lipo Protein Equal variances assumed

Equal variances not assumed

**ent Samples Test** 2 6

5 5

.

4 .

3 6

8 4

8

2 7

5 6

.

4 .

3 6

8 4

8

8 7

. 6

4

0 3

4 3

.

8 9

. 3

4 4

0

4 3

3

. .

3 9

4 3

3 4

5

9 2

7

. .

3 8

4 0

3 9

5

9 2

7

7 .

. 8

0 0

6 9

5

2

7 8

. .

0 9

3

1

28.931

-38.014 **ent Samples Test** 7

**Independ**

|  |  |  |
| --- | --- | --- |
| 2 | | 44 |
| 7 |  |  |
| . |  | 48.629 |
| 0 |  |  |
| 0 |  | 49.081 |
| 4 |  |  |
|  | 1 |  |
| . |  |  |
| 6 |  |  |
| 7 |  |  |
| 8 |  |  |
| 8 |  |  |
| 6 |  |  |
|  | 1 |  |
| . |  |  |
| 6 |  |  |
| 7 |  |  |
| 9 |  |  |
| 3 |  |  |
| 0 |  |  |
|  | 1 |  |
| 0 |  |  |
| 3 |  |  |
| . |  |  |
| 7 |  |  |
| 7 |  |  |
| 7 |  |  |
|  | 1 |  |
| 0 |  |  |
| 4 |  |  |
| . |  |  |
| 0 |  |  |
| 4 |  |  |
| 1 |  |  |
|  | 5 |  |
| 9 |  |  |
| . |  |  |
| 4 |  |  |
| 6 |  |  |
| 2 |  |  |
|  | 6 |  |
| 0 |  |  |
| . |  |  |
| 4 |  |  |

5

-38.109 .

3

-18.391 4

7

-18.839

7

-.74890 5

.

-.75047 4

4

-6.242 2

-8.004 1

9

-1.21219 .

0

-1.21264 5

8

-47.444

1

-47.707 9

.

-64.462 5

0

-65.444 5

-80.296 .

7

-80.748 8

2

2

4

.

7

8

3

8

1

2

5

. 2

4

2

**Independent Samples Test**

Levene's Test for Equality of Variances t-test for Equality of

Very Low Density Lipo Protein

Equal variances assumed

Equal variances not assumed

F S

i .

1 g 2

. . 5

4 1

8

5

t

-.142

-.142

High Density Lipo Protein Equal variances assumed

Equal variances not assumed

S Bilirubin Total Equal variances assumed

Equal variances not assumed

S Bilirubin Direct Equal variances assumed

Equal variances not assumed

S Bilirubin Indirect Equal variances assumed

. . .926

4 5

3 2 .926

5 5

.700

.700

. 1 -.976

0 .

0 0 -.976

0 0

0 -.336

4

. .

7 0

2 5

3 5

1 .

. 2

5 4

2 5

4

Aspartate Trans Amines

(AST)

Alanine

T es (ALT)

r A

a m

n i

s n

Equal variances not assumed

Equal variances assumed

Equal variances not assumed

Equal variances assumed

Equal variances not assumed

**Independent Samples Test** -

.

1.524 . 3

2 3

4 6

5

.

.000 1

9

0

1

. .

0 1

0 9

0 0

.

4

4

1

Creatine Phosphate K Equal variances assumed

Equal variances not assumed

CPK - Muscular / Brain Equal variances assumed

Equal variances not assumed

GGT Equal variances assumed

Equal variances not assumed

.

4

4

1

1 . .032

7 0

. 0 .032

5 2

7 .494

8

.494

. .779

6

. 2 .779

2 1

6

1

.

3

. 9

7 4

9

2

**Independent Samples Test**

t-test for Equality of Means

Very Low Density Lipo Protein

Equal variances assumed

df Sig. (2-taile

Mean Difference

-1.667 90

d) 10 .8

Equal variances not assumed 7 .

High Density Lipo Protein Equal . 8

variances assumed 0 9

1 1

Equal variances not assumed 6

S Bilirubin Total Equal variances . assumed

|  |  |  |  |
| --- | --- | --- | --- |
| 1 | 3 |  | .23333 |
| 0 | 7 |  |  |
| 9 | 6 |  | .23333 |
| .  4 | 3 | . | -.48333 |
| 9 | 7 |  | -.48333 |
| 0 | 7 |  |  |

Equal variances not assumed

S Bilirubin Direct Equal variances assumed

Equal variances not assumed

S Bilirubin Indirect Equal variances

assumed 1 .

0 5

0

1 0

0

. .

0 5

0 0

0 0

-1.667

6.000

6.000

-.13333

1 .

0 3

5

5 2

.

5 .

0 3

3 7

0

1

0 .

7

4

4

Equal

**Independent Samples Test**

~~8~~  .

-.13333

Aspartate Trans Amines (AST)

Alanine Trans Amines (ALT)

variances not . 7

assumed 8 4

Equal 3 4

variances 3

assumed .

1 8

Equal 0 5

variances not 3

assumed 9

Equal . .

variances 7 8

assumed 1 5

4 3

Equal

variances not 1 .

assumed 0 6

6

1 9

0

. .

0 6

0 6

0 9

1.333

1.333

3.333

3.333

Creatine Phosphate K Equal variances 1 .

assumed 0 6

2

Equal variances not assumed 3

CPK - Muscular / Brain Equal variances 7

assumed .

8

Equal variances not assumed 8

GGT Equal variances 9

assumed 1

Equal variances not assumed 0

1

0

. 0

0

0

.975

.975

.632

.632

.454

.455

1

0

9

.333 **ent Samples Test**

**Independ**

.333

3.667

3.667

2.333

2.333

**Independent Samples Test**

t-test for Equality of Means 95% Confidence Interval of the

S

td.

Difference Lower Upper

Very Low Density Lipo Protein

Equal variances assumed

Equal variances not assumed

Err or Dif fer enc e

1

1.7

74

-27.900 24.567

-29.494 26.161

High Density Lipo Protein Equal variances assumed

Equal variances not assumed

S Bilirubin Total Equal variances assumed

Equal variances not assumed

S Bilirubin Direct Equal variances assumed

Equal variances not assumed

S Bilirubin Indirect Equal variances assumed

1

1.7

74

6 5

. 3

4 7

8

1 .

4

6 9

. 5

4 3

8 7

1

.

. 3

3 9

3 6

3 3

3 7

3

.

3

3

3

3

3

- 8.440

- 8.546

-

.50938

-

.50938

- 1.58708

- 1.72250

- 1.01651

.

4

9

20.440

20.546

.97605

.97605

**ent Samples Test**

. . .7498

**Independ**

6 7 4

2 5

0

4

1

5

8

3

Aspartate Trans Amines (AST)

Alanine Trans Amines

Equal variances not assumed

Equal variances assumed

Equal variances not

. -

3 1 2

9 .

6 0

3 3 7

7 2

5

7 8 0

.

.7659

16.93

17.00

(ALT) assumed

Equal variances assumed

Equal variances not assumed

0 -

0 1 2

3 4

.

7 2 2

. 7

0 1

0

3 -

1

7 4

. .

5 3

5 3

7 3

20.17

20.17

7 -

. 1

5 3

5 .

7 5

0

5

-

1

3

. 5

0

5

Creatine Phosphate K Equal variances a s sumed

Equal variances not assumed

**Independent Samples Test**

CPK - Muscular / Brain Equal variances assumed

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | 1 |  | - | 23.24 |
| 0 |  | 2 |  | 0 |
| . |  | 2 |  |  |
| 2 |  | . |  | 24.09 |
| 8 |  | 5 |  | 8 |
| 1 |  | 7 |  |  |
|  |  | 3 |  | 20.20 |
| 0 | 1 |  | - | 3 |
| . |  | 2 |  | 20.20 |
| 2 |  | 3 |  | 3 |
| 8 |  | . |  |  |
| 1 |  | 4 |  | 9.009 |
|  |  | 3 |  |  |
| . | 7 | 2 |  | 9.045 |
| 4 |  |  | - |  |
| 2 |  | 1 |  |  |
| 1 |  | 2 |  |  |
|  |  | . |  |  |
|  | 7 | 8 |  |  |
| . |  | 6 |  |  |
| 4 |  | 9 |  |  |
| 2 |  |  |  |  |
| 1 |  |  | - |  |
|  |  | 1 |  |  |
| . | 2 | 2  . |  |  |
| 9 |  | 8 |  |  |
| 9 |  | 6 |  |  |
| 6 |  | 9 |  |  |
| . | 2 | 4 | - |  |
| 9 |  | . |  |  |
| 9 |  | 3 |  |  |
| 6 |  | 4 |  |  |
|  |  | 3 |  |  |
|  |  |  | - |  |
|  |  | 4 |  |  |
|  |  | . |  |  |
|  |  | 3 |  |  |
|  |  | 7 |  |  |
|  |  | 8 |  |  |

Equal variances not assumed

GGT Equal variances assumed

Equal variances not assumed

**Independent Samples Test**

Levene's Test for Equality of

Variances

t-test for

Equality of

F

Sig.

t

T - Protein

Equal variances assumed

4.386

.063

Equal variances not

assumed

-.851

Albumin .000 1.000 .675

Equal variances not

assumed

.675

Globulin .000 1.000 -.154

Equal variances not

assumed

-.154

t-test for Equality of Means

df

Sig. (2-tailed)

Mean

Difference

T - Protein

Equal variances assumed

Equal variances not assumed

7.102

.422

-.63333

Albumin 10 .515 .43333

Equal variances not

assumed

9.998

.515

.43333

Globulin 10 .881 -.10000

Equal variances not

assumed

9.990

.881

-.10000

# Independent Samples Test

**Independent Samples Test**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | t-test for Equality of Means | | |
| St  d. Erro r Diff  eren ce | 95% Confidence  Interval of the Difference | |
| Lo wer | U  pper |
| T -  Protein | Equal variances  assumed | .7  441  6 | - 2.29  143 | 1.  024  76 |
|  | Equal variances not assumed | .7  441  6 | - 2.38  790 | 1.  121  24 |
| Albu min | Equal variances  assumed | .6  422  2 | -  .997  62 | 1.  864  29 |
|  | Equal variances not assumed | .6  422  2 | -  .997  66 | 1.  864  33 |
| Globu lin | Equal variances  assumed | .6  491  0 | - 1.54  629 | 1.  346  29 |
|  | Equal variances not assumed | .6  491  0 | - 1.54  649 | 1.  346  49 |

ONEWAY BSF BSP BSR UREA CREATINE SODIUM POTASSIUM LTC LTG LDLP VLDLP HDLP SBT SBD SBI AST ALT CPK CPKMB GGT TP ALBUMIN GLOBULIN AGRATIO BY

Age

/MISSING ANALYSIS.

# Oneway

[DataSet1] C:\Users\Ritika.DESKTOP-730O9R4\Desktop\phd data final\JS SIR DATA

.sav

**ANOVA**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Su m of Squ ares | d  f | M  ean Squ  are | F |
| Blood Sugar Fasting  Between  Groups | 61  .800 | 2 | 3  0.9  00 | .  1  6  2 |
| Within Groups | 17  21.8  67 | 9 | 1  91.  319 |
| Total | 17  83.6  67 | 1  1 |  |
| Blood Sugar Post - Between Groups | 17  28.2  00 | 2 | 8  64.  100 | .  6  3  5 |
| Prandial Within Groups | 12  245.  467 | 9 | 1  360  .60  7 |
| Total | 13  973.  667 | 1  1 |
| Blood Sugar Random  Between  Groups | 34  52.2  00 | 2 | 1  726  .10  0 | .  9  1  3 |
| Within Groups | 17  006.  467 | 9 | 1  889  .60  7 |
| Total | 20  458.  667 | 1  1 |
| Urea Between  Groups | 17  8.33  3 | 2 | 8  9.1  67 | .  4  1  4 |
| Within Groups | 19  40.6  67 | 9 | 2  15.  630 |
| Total | 21 | 1 |  |

**ANOVA**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | 19.0  00 | 1 |  |  |
| Creatine Between Groups | .1  96 | 2 | .0  98 | .  2  6  3 |
| Within Groups | 3.  347 | 9 | .3  72 |
| Total | 3.  543 | 1  1 |  |
| Sodium Between Groups | 35  9.58  3 | 2 | 1  79.  792 | 1  . 1  4  9 |
| Within Groups | 14  08.6  67 | 9 | 1  56.  519 |
| Total | 17  68.2  50 | 1  1 |  |
| Potassium Between Groups | .3  05 | 2 | .1  53 | .  1  1  0 |
| Within Groups | 12  .485 | 9 | 1.  387 |
| Total | 12  .790 | 1  1 |  |
| Lipid T - Cholesterol  Between  Groups | 73  5.45  0 | 2 | 3  67.  725 | .  0  9  1 |
| Within Groups | 36  190.  800 | 9 | 4  021  .20  0 |
| Total | 36  926.  250 | 1  1 |
| Lipid Tri - Glyceride  Between  Groups | 21  82.2  50 | 2 | 1  091  .12  5 | .  4  6  7 |
| Within Groups | 21  036. | 9 | 2  337 |

**ANOVA**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Total | 667 | 1  1 | .40  7 |  |
| 23  218.  917 |
| Low Density Lipo Protein  Between  Groups | 36  9.45  0 | 2 | 1  84.  725 | .  0  6  5 |
| Within Groups | 25  492.  800 | 9 | 2  832  .53  3 |
| Total | 25  862.  250 | 1  1 |
| Very Low Density Lipo  Between  Groups | 12  32.1  33 | 2 | 6  16.  067 | 1  . 8  8  9 |
| Protein Within Groups | 29  34.8  67 | 9 | 3  26.  096 |
| Total | 41  67.0  00 | 1  1 |  |
| High Density Lipo Protein  Between  Groups | 19  6.80  0 | 2 | 9  8.4  00 | .  7  5  6 |
| Within Groups | 11  71.2  00 | 9 | 1  30.  133 |
| Total | 13  68.0  00 | 1  1 |  |

**ANOVA**

|  |  |  |
| --- | --- | --- |
|  | | S  i g  . |
| Blood Sugar Fasting | Betw een Groups Within Groups  Total | .  8  5  3 |
| Blood Sugar Post - Prandial | Betw een Groups Within Groups  Total | .  5  5  2 |
| Blood Sugar Random | Betw een Groups Within Groups  Total | .  4  3  5 |
| Urea | Betw een Groups Within Groups  Total | .  6  7  3 |
| Creatine | Betw een Groups Within Groups  Total | .  7  7  4 |
| Sodium | Betw een Groups Within Groups  Total | .  3  5  9 |
| Potassium | Betw een Groups Within  Groups | .  8  9  7 |

**ANOVA**

|  |  |  |
| --- | --- | --- |
| Total | |  |
| Lipid T - Cholesterol | Betw een Groups Within Groups  Total | .  9  1  3 |
| Lipid Tri - Glyceride | Betw een Groups Within Groups  Total | .  6  4  1 |
| Low Density Lipo Protein | Betw een Groups Within Groups  Total | .  9  3  7 |
| Very Low Density Lipo Protein | Betw een Groups Within Groups  Total | .  2  0  7 |
| High Density Lipo Protein | Betw een Groups Within Groups  Total | .  4  9  7 |

S Bilirubin Total Between Groups Within Groups Total

S Bilirubin Direct Between Groups Within Groups Total

S Bilirubin Indirect Between Groups Within Groups Total

**ANOVA**

S

u m of Sq ua res

. 77

5

2

df Mean Squar 9 .302

11

2 .320

9 .825

11

2 .024

9 .524

F 1.281

.388

e 2

.046

.387

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | .7 | 11 |  |
| 22 |  |
| 3 |  |
| .4 |  |
| 97 |  |
| . 64 |  |
| 1 |  |
| 7 |  |
| .4 |  |
| 22 |  |
| 8 |  |
| .0 |  |
| 63 |  |
| . 04 |  |
| 8 |  |
| 4 |  |
| .7 |  |
| 19 |  |
| 4 |  |
| .7 |  |
| Aspartate | Betw | 67  G | l | 128.80 |
| Trans Amines | een | r |  | 0 |

Trans Amines (ALT)

Betw T

een o

|  |  |  |
| --- | --- | --- |
| (AST) | Groups | o |
| Alanine | Within Groups Total | u p s |

Groups t

Within a

1347.8

67

1476.6

67

97.800

1648.8

67

1746.667 2 64.400

9

149.76

3

**ANOVA** .

4

3

0

11

2

9

183.20

7

48.900 .

2

6

7

11

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 11  Creatine Phosphate K Between |  | 3 |  | 800 | 2 |  | |
| Groups  Within Groups Total  CPK - Muscular / Brain Between Groups  Within Groups Total  GGT Between  Groups  Within Groups Total  T - Protein Between Groups Within Groups Total  Albumin Between Groups Within Groups Total  Globulin Between Groups Within Groups Total  A : G Ratio Between Groups Within Groups Total | 2  5  . 8  0  0  8  4  5  . 2  0  0  1  7 | 2  3 |  | 1692.66  7  9.200  276.467  285.667  .362  17.455  17.817  1.202  11.735  12.937  11.709 | 62.900  9  16.133  2  04.933  9  64.756  2  9 | 1  3  1  1 | 4.600 |
|  | 1 |  |  | 12.670 |  |  |  |
|  | . 0  0  0 | 2 |  | .000  .000  .000 | 30.719  11  2  9 |  | .181  1.939 |
|  | 0 |  |  |  | 11 |  |  |
|  | 9  . 8 |  |  |  | 2  9 |  | .601  1.304 |
|  | 6 |  |  |  | 11 |  |  |
|  | 7 |  |  |  | 2 |  | .481 |
|  | 4  8 | 1 |  |  | 9  11 |  | 1.301 |
|  | 2  . |  |  |  | 2 |  | .000 |

11

.961

9 .000

11

**ANOVA** .

5

1

5

.

6

3

7

.

1

5

0

.

0

9

3

.

4

6

1

.

3

6

9

.

|  |  |  |
| --- | --- | --- |
|  | | S  **A**i**NOV**  g  . |
| S Bilirubin Total | Betw een Groups Within Groups  Total | .  3  2  4 |
| S Bilirubin Direct | Betw een Groups Within Groups  Total | .  6  8  9 |
| S Bilirubin Indirect | Betw een Groups Within Groups  Total | .  9  5  5 |
| Aspartate Trans Amines (AST) | Betw een Groups Within Groups  Total | .  6  6  3 |
| Alanine Trans Amines (ALT) | Betw een Groups Within Groups  Total | .  7  7  2 |
| Creatine Phosphate K | Betw een Groups Within Groups  Total | .  6  1  4 |
| CPK -  Muscular / Brain | Betw een Groups Within Groups  Total | .  5  5  1 |
| GGT | Betw een Groups  Within Groups | .  8  6  3 |

**A**

**A**

|  |  |  |
| --- | --- | --- |
| Total | | **ANOV** |
| T - Protein | Betw een Groups Within Groups  Total | .  9  1  2 |
| Albumin | Betw een Groups Within Groups  Total | .  6  4  5 |
| Globulin | Betw een Groups Within Groups  Total | .  7  0  1 |
| A : G Ratio | Betw een Groups Within Groups  Total | . |

* 1. Discussion attempts to observe findings, insights and knowledge by juxtaposing business entrepreneurship optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) with hematology. Thesis intends to help business entrepreneurships develop judgment in optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) skills. Hematologically, do they really have a optimum preference neurofeedback? How do hematological ‘concepts’ exist and influence? How hematological observations are integrated into ‘business entrepreneurship activity’? How can business entrepreneurships change behavioural optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) attitudes? Fluctuating blood glucose levels affect optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making. Studies indicate connection between blood count levels and cognitive thinking. Monitoring degree of fluctuation in blood counts offers possible inferences. There is a need to study biological underpinnings of business entrepreneurship about how biology and blood monikers interact to shape business entrepreneurship behaviour. There are limited longitudinal, ambulatory / diary and dearth of research undertaking a cognitoscientific investigation of the phenomenon. In addition, various biological neuro - agents are not mutually exclusive and it is unclear how they may interrelate. There is little work on relationship between biology and opportunity recognition, influence of biology at different phases of start-up process and how being a business entrepreneurship may affect biological processes. To provide a fundamental basis for understanding optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making and optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) confidence, we analysed blood samples concontemporaryly with a optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) - testing questionnaire was served to each subject. The samples are of those respondents with standing history of hypertension and were selected grounded on previous blood pressure control. It is observed that almost all ‘hematological monikers’ reflect disturbing trends.

110

* 1. Thesis submits an experiment in exploring optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making behaviour via haematological acuities. Administering a situation reaction test, in empirical part, aseries of clinical observations (over a four year observation period in phases) were administered to 150 sub**A**j**N**e**O**ct**V**s**A**(n = 150; n = 80 Male subjects and n = 70 Female subjects). This design was favoured due to element of plasticity and variations in response to intervention

effects. This was done to ensure that subject serves as own control. Blood samples were drawn, calibrated and substantiated. Inter - correlational analysis has been conducted. This assured and ensured continuous assessment, reference point valuation and variability in ‘inferential’ data. Analysis depicts that blood groups do have a role in business entrepreneurship optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) dynamics. Results indicate role of ‘hematological undercontemporarys’ in business entrepreneurship optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making apparatus. Inference is inferred to be sound and justified in that optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making of a business entrepreneurship are linked to (biological and) hematological aspects.

* 1. Hematological ‘inferential’ data presented is experiential that in a state of normalcy, hematological indices are normal within the normal range. However, in a stressful condition, there is a drastic drop in the indices like Blood Sugar Fasting, Blood Sugar Post - Prandial, Blood Sugar Random, Urea, Creatine, Sodium, Potassium, Lipid T - Cholesterol, Lipid Tri - Glyceride, Low Density Lipo Protein, Very Low Density Lipo Protein, S Bilirubin Total, S Bilirubin Direct, S Bilirubin Indirect, Aspartate Trans Amines (AST), Alanine Trans Amines (ALT), Creatine Phosphate K, CPK - Muscular / Brain, T - Protein, Albumin and Globulin. However, minor drops have been experiential in parameters like Creatine, CPK - Muscular / Brain, T - Protein, Albumin and Globulin. Question is whether young male business entrepreneurships harbour lack of ‘perfect’ resilience to absorb shocks in business. Question is whether middle - aged male business entrepreneurships have mixed - resilience to absorb shocks in business? Question is whether aged male business entrepreneurships have heavy resilience to absorb shocks in business. Question is whether middle - aged female business entrepreneurships have heavy (surprising results!) resilience to absorb shocks in business. Question is whether aged female business entrepreneurships have heavy (surprising results!) resilience to absorb shocks in business.
  2. **Inference - 1:** Drastic Drop is experiential in Blood Sugar Fasting, Blood Sugar Post - Prandial, Blood Sugar Random, Urea, Sodium, Potassium, Lipid T - Cholesterol, Lipid Tri - Glyceride, Low Density Lipo Protein, Very Low Density Lipo Protein, S Bilirubin Total, S Bilirubin Direct, S Bilirubin Indirect, Aspartate Trans Amines (AST), Alanine Trans Amines (ALT), Creatine Phosphate K, CPK - Muscular / Brain, T – Protein and Albumin. Minor drop is experiential Creatine, CPK - Muscular / Brain, T - Protein, Globulin, Albumin and Globulin. Question is whether young male business entrepreneurships have lack of ‘perfect’ resilience to absorb shocks in business. In such a case, business entrepreneurships feel a state of tiredness, weariness, exhaustion, overtiredness, lethargy, sluggishness, lassitude, debility, enervation, listlessness, prostration, lack of energy, lack of vitality, tired, wear out, drain, make weary, weary, wash out, tax, overtax, overtire, jade, make sleepy. May be, race against time to achieve targets leads to stress symptoms that affect body, thoughts, feelings and behaviour.
  3. **Inference - 2:** It is experiential that in a state of normalcy, hematological indices are normal within the normal range. However, in a stressful condition, there is a drastic drop, as well as minor drop, in the indices like Blood Sugar Fasting, Blood Sugar Post - Prandial, Blood Sugar Random, Urea, Creatine, Sodium, Potassium, Lipid T - Cholesterol, Lipid Tri - Glyceride, Low Density Lipo Protein, Very Low Density Lipo Protein, S Bilirubin Total, S Bilirubin Direct, S Bilirubin Indirect, Aspartate Trans Amines (AST), Alanine Trans Amines (ALT), Creatine Phosphate K, CPK - Muscular / Brain, T - Protein, Albumin and Globulin. Question is whether middle - aged male business entrepreneurships have mixed - resilience to absorb shocks in business. It is assumed that business entrepreneurships have put in some appreciable quantum of business - experience. They are by now well - versed with the dynamics of business in a complex but informative world. The middle - aged business entrepreneurships have nearly consolidated in their business and business entrepreneurship activities. May be, earning profits is no longer the macro - aim but consolidation of business in the roller coaster series of profit - loss enables them to absorb the drop in glucose levels and their associated effects. Hence, minor drop, in indices.

111

* 1. **Inference - 3:** It is experiential that in a state of normalcy, hematological indices are normal within near - normal range. However, in a stressful condition, there is a drastic drop, as well as minor drop, in the indices like Blood Sugar Fasting, Blood Su**A**g**N**ar**OV**P**A**ost - Prandial, Blood Sugar Random, Urea, Creatine, Sodium, Potassium, Lipid T - Cholesterol, Lipid Tri - Glyceride, Low Density Lipo Protein, Very Low Density Lipo Protein, S Bilirubin Total, S Bilirubin Direct, S Bilirubin Indirect, Aspartate Trans Amines

(AST), Alanine Trans Amines (ALT), Creatine Phosphate K, CPK - Muscular / Brain, T - Protein, Albumin and Globulin. It is experiential that majority of the indices have registered minor drops. Question is whether aged male business entrepreneurships have heavy resilience to absorb shocks in business. In such a scenario, either business entrepreneurship is cruising in business after a long - period of seasoned business acumen, or has adopted his off - springs to his business activities. Wealth, in any form, accumulation must have been ensured or assured by now. Business shocks are no longer a deterring neuro - agent. Ethical framework becomes no longer a burdensome constraint. Emphasis is on ethical integrity of individual business entrepreneurship - neuro - agents. A spiritual sense of satiety has perhaps been achieved.

* 1. **Inference - 4:** It is experiential that in a state of normalcy, hematological indices are normal within the normal range. However, in a stressful condition, there is a drastic drop, as well as minor drop, in the indices like Blood Sugar Fasting, Blood Sugar Post - Prandial, Blood Sugar Random, Urea, Creatine, Sodium, Potassium, Lipid T - Cholesterol, Lipid Tri - Glyceride, Low Density Lipo Protein, Very Low Density Lipo Protein, S Bilirubin Total, S Bilirubin Direct, S Bilirubin Indirect, Aspartate Trans Amines (AST), Alanine Trans Amines (ALT), Creatine Phosphate K, CPK - Muscular / Brain, T - Protein, Albumin and Globulin. It is experiential that majority of the indices have registered mixed drops. In contrast to their male counterparts, females have registered mixed fluctuations indicating ‘good’ levels of tolerance. It can be safely assumed that they can tolerate (or survive within) a certain range of a particular neuro - agent, but cannot survive if there is too much or too little of the neuro - agent. They perhaps subscribe to an allowable departure from a specification or standard, considered non - harmful to functioning of a part, process, or product over its life cycle. They have ability to withstand high levels of stress or overloading (‘mental effort’) without suffering irreparable harm.
  2. It is pragmatic that in a state of normality, Hematological (CBC) indices are normal within standard range. However, in nerve-wracking situation, there is a sweeping globule in indices like Blood Sugar Fasting, Blood Sugar Post – Prandial, Blood Sugar Random, Urea, Creatine, Sodium, Potassium, Lipid T
* Cholesterol, Lipid Tri - Glyceride, Low Density Lipo Protein, Very Low Density Lipo Protein, S Bilirubin Total, S Bilirubin Direct, S Bilirubin Indirect, Aspartate Trans Amines (AST), Alanine Trans Amines (ALT), Creatine Phosphate K, CPK - Muscular / Cerebrum, T - Protein, Albumin and Globulin. Nonetheless, inconsequential drops have been experiential in constraints like Creatine, CPK - Muscular / Cerebrum, T - Protein, Albumin and Globulin. Question is whether male business entrepreneurships have lack of ‘perfect’ pliability to absorb shocks in business. To offer a central basis for appreciative optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making and optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) buoyancy, Satpathy and Mallik (2008) analysed blood samples synchronously with optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) - testing questionnaire. The sample was of those respondents with standing history of hypertension and selected grounded on previous poor blood pressure control. It is apparent that almost all the Hematological (CBC) Monikers reflect disturbing trends. Results designate role of ‘Hematological (CBC) tinges’ in business entrepreneurship resolution contraption. Inference is comprehensive and reasonable in that resolution of an business entrepreneurship is linked to biological and Hematological (CBC)aspects.
  1. Grounded on experimental tests (Satpathy, J. et. al.; 2018), it is inferred that; resolution probable is bad when;
  + Blood sugar fasting readings are supposed as ‘inconsistent’,
  + Blood sugar post - prandial readings are supposed as ‘inconsistent’,
  + Blood sugar random readings are supposed as ‘inconsistent’,

112

* + Urea readings are supposed as ‘inconsistent’
  + Creatine readings are supposed as ‘inconsistent’,
  + Sodium readings are supposed as ‘inconsistent’,
  + Potassium readings are supposed as ‘incons**A**is**N**te**O**n**V**t**A**’,
  + S Bilirubin Direct readings are supposed as ‘inconsistent’,
  + S Bilirubin Indirect readings are supposed as ‘inconsistent’,
  + Aspartate TransAmines readings are supposed as ‘inconsistent’,
  + Alanine TransAmines alt readings are supposed as ‘inconsistent’,
  + Lipid T - Cholesterol readings are supposed as ‘inconsistent’,and
  + Lipid Tri - Glyceride readings are supposed as ‘inconsistent’.
  + Low-density lipo protein readings are supposed as ‘inconsistent’,
  + Very low-density lipo protein readings are supposed as ‘inconsistent’,
  + High density lipo protein readings are supposed as ‘inconsistent’,
  + S bilirubin total readings are supposed as ‘inconsistent’,
  + Creatine Phosphate K readings are supposed as ‘inconsistent’,
  + CPK - muscular / cerebrum readings are supposed as ‘inconsistent’,
  + GGT readings are supposed as ‘inconsistent’,
  + T - Protein readings are supposed as ‘inconsistent’,
  + Albumin readings are supposed as ‘inconsistent’,
  + Globulin readings are supposed as ‘inconsistent’,
  + A: G ratio readings are supposed as ‘inconsistent’,
  1. Anthropoid ‘agents’ rely on guarded mock - up of cognitobusiness entrepreneurship resolution modeling. The two experimentations (conducted by the first author) depict that optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)-making is a province of penetrating study in cognito - management and cerebral bio - human science. Psychosomatic mockups of resolution elucidate that Anthropoid ‘agents’ progressively accrue signal for a specific optimum preference neurofeedback over stretch and accomplish that optimum preference neurofeedback when confirmation scopes a critical path. This characterizes a multidisciplinary and multi-method tactic to conceptualization of management and optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)agents. Results depict data visualizations that interconnect significant facets of visual behaviour. Above disclose show position, direction and time spent observing at locations on stimulus. Above results depict time matrix of perceiving or where subject(s) look. Above results depict, how ‘observing’ is dispersed over stimulus. Key finding is that tactical - oriented ‘Neuro - agent’ chooses, generate optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s, address responses to optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) ‘circuit’ problems and evaluates métiers of ‘circuit’ using cognito - ‘cognito’ medium. Experimentation deliberates outcomes and future guidelines to directed cognito - ‘cognito’ biology in optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) scholarship.

# INFERENCES

* 1. The international weekly news thesis, ‘The Economist’ opined that behavioral management is best discernible as a set of deviations and anomalies that improves yet augments the accepted prototype of logical selection, not least as it is illogical to assume that people mostly behave illogically.
  2. Resolutions and judgments are unavoidable part of business entrepreneurship engagements within the scope of activities in routine life. While there are postulations in theory, propounding discernible neural calculations, management had no concrete elucidation to some pragmatic and factual questions it could construct and contrive in inferring solutions and making optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s. Over the last decade, insightful management has depicted cogent and significant explications and results through demonstrations, trials and m1o13nitoring.

Insightful management has built up and added value to conclusive, scientific understanding facilitating

inferences rather than suppositions and speculations that cannot be proved. With varied disciplines

approaching symptomatically dissimilar practices and significant progresses, insightful resolution propositions tools for modeling deportment on how business entrepreneurships design and resolve via neural basis.

**ANOVA**

* 1. Calculated cognito - ‘cognito ‘optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s generally involve risk. Results, with reference to business entrepreneurship cognito - ‘cognito’ optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) germaneness and implications, demonstrate indications for spontaneous counterfactual replication in province of high - level cognito - ‘cognito’ reasoning. Key finding is that tactical - oriented ‘neuro - agent’ decides, create options, address responses to cognito - ‘cognito’optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) ‘circuit’ problems and evaluates métiers of ‘circuit’ using cognito - ‘cognito’ medium. Thesis advocates outcomes and future directions to guided cognito - ‘cognito’ biology in optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) scholarship. Cognito - ‘cognito’ complex provides graining that propositions curtains of business entrepreneurship cognito - ‘cognito’ ‘modulator - demodulator’ to answer issues in business entrepreneurship optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) configuration dynamics. These observations extend the outcomes of recent behavioral studies.
  2. In an uncertain world, where optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s encompass an element of ‘risk’, this thesis asserts that there is a ‘hemato - genetic effect’ to business entrepreneurship optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) making. New review prompts a re-think on what low sugar levels affects our thinking (Satpathy et. al.; 2018). Notwithstanding wide-ranging research approaches in blood glucose literature, one finding stands conveyed clearly; blood count levels affect reasoning performance. There are many gaps in knowledge and aim was to discuss ways to take this inquiry forward. Future research could incorporate evolutionary sensibility and interactive heredities. Inferences drawn are that tactical - oriented ‘neuro - agent - business entrepreneurship’ decides, create options, address responses to cognito - ‘cognito’ optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) ‘circuit’ problems and evaluates métiers of ‘circuit’ using cognito - ‘cognito’ medium.

# References

1. Deo, M. and Satpathy, J. (2018).Hematological Insight into Business entrepreneurship Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s), 71st All India Commerce Conference, 20-22 Dec, Department of Commerce, Osmania University, Hyderabad, India.(National).
2. Mishra, B.P. and Satpathy, J. (2019). Business entrepreneurship Resolution, Journal of Personnel Focus, ISSN: 2229 - 6506, Vol. 14, Issue (3), July, Pp: 01 - 07, Bhubaneswar, India (National).
3. Satpathy, J. (2018). Cognito - Grounded Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s in Global Business Undercontemporarys, IMS International Conference on Indian Trade and Commerce: Past, Present and Future, March 18, Bhubaneswar, India (International).
4. Satpathy, J. (2019). Cognito - Optometric Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) Estimates in Managing Creative Organization (Poster), 4th Coller Conference on Behavioral s (CCBE), 19 - 20 June 2019, Center for Behavior Change, Tel Aviv University, Israel (International).
5. Satpathy, J. (2020). Cognito - Perspectives in Business entrepreneurship Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s: An Anthology, Odisha Journal of Social Science, OJSS, Vol.7, Issue - 1, Pp: 60 - 66 Jan, 2020, Bhubaneswar, Odisha, India (National).

114

1. Satpathy, J. (2020). Cognito - Trajectories in Resolution, Proceedings of 5th International Conference (INCONSYM 2020) on Business Transformation in Global Digital Era: Re-Innovator - Strategize and Re - Model, 21 - 22 Feb 2020, Symbiosis Centre for Management Studies, Symbiosis University, NOIDA, Delhi, India (International).**NOVA**

**A**

1. Satpathy, J. (2020). Cognito - Trajectories in Technology - Driven Business entrepreneurship Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s, Proceedings of International Conference on Research, Innovation, Knowledge Management and Technology Application for Business Sustainability, 19 - 21 Feb 2020, INBUSH ERA World Summit, Amity University, NOIDA, India (International).
2. Satpathy, J. and Banerji, J. S. (2019). Cognito - ‘Agent’ in Business Transformation, A Journal of Composition Theory, UGC - CARE Group ‘A’ Journal Approval Number: 18482, Volume XII, Issue VII, July, Pp: 426-442, DOI: 19.18001.AJCT.2019.V12I7.19.10048, Karnataka, India (National). Reprinted in IUJ Journal of Management (IUJJOM), ISSN : 2347 – 5080, EOI: 10.11224 / IUJ, Volume7, Issue.2, December, ICFAI University Jharkhand, India (National). .
3. Satpathy, J. and Banerji, J. S. (2019).Cognito - Monikers in Business entrepreneurship Behaviour, Poster Thesis, Society for Judgment and Resolution (SJDM) Conference, 15 - 18 November 2019, Montreal, Canada (International).
4. Satpathy, J. and Banerji, J. S. (2019).Oculo - Tactical Monikers in Business entrepreneurship Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s), Proceedings of Global Management Research and Education: Challenges and Opportunities (GOMRECA 2019) Conference, 09 - 10 Aug 2019, Dept. of Management, International School of Management (ISM),Patna, Bihar, India (National).
5. Satpathy, J. and et. al. (2018). Thoughts on Business entrepreneurship Skills, National Institute of Personnel Management, Utkal Chapter, Vol. 14, Issue No. 1, ISSN No. 2229 - 6506, Pp: 01 - 06, January 2018, Bhubaneswar, India (National).
6. Satpathy, J. and et. al. (2019). Cognito - Diagonals in Business entrepreneurship Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s, Proceedings of National Conference on Strategic Human Resources Management : A Global Perspective, 13 Sep 2019, Dept. of Management, St Mary’s College (Autonomous), Toothukudi, Tamil Nadu,India(National).
7. Satpathy, J. and Gera, S. (2020). Random Reflections on Cognitooptimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s Dynamics, Odisha Journal of Social Science, OJSS, Vol.7, Issue - 1, Pp: 67 - 74 Jan, 2020, Bhubaneswar, Odisha, India (National).
8. Satpathy, J. and Hejmadi, A. (2018). Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) Signatures in Business entrepreneurship Brain Architecture (Poster), Proceedings of CognitoPsychos Conference, Pp: 61, May 24 - 25, Zurich, Switzerland.(International).
9. Satpathy, J. and Hejmadi, A. (2019).Electrodermal Traces in Resolution, Proceedings of National Seminar on Technology, Innovation, Policy Initiatives and Business entrepreneurship Development (NSTIPED - 2019), 30th - 31st Jan 2019, Parala Maharaja Engineering College, BPUT University, Berhampur, Odisha, India (National).
10. Satpathy, J. and Hejmadi, A. (2019).Business entrepreneurship Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) Uncertainties In VUCA Spectrum, Proceedings of National Seminar on Issues and Challenges in VUCA World, 23 Mar 2019, ICBM - School of Business Excellence, Hyderabad, Telengana, India (Adjudged as Outstanding Research Thesis) (National).
11. Satpathy, J. and Hejmadi, A. (2019).Cognito - Optometric Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) Estimates in Managing Creative Organisation,

115

Proceedings of National Seminar on Managing Resource through Creativity for Generating Opportunities in 21st Century, Pp: 30 - 55, ISBN Number: 978 - 81 - 922746 - 9 - 0, S B Patil Institute of Management, Pune University, 18 -19 Jan 2019, Pune, India (National).

**ANOVA**

1. Satpathy, J. and Hejmadi, A. (2019).Cognito - Optometric Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) Estimates in Managing Creative Organisation, Proceedings of National Seminar on Managing Resource through Creativity for Generating Opportunities in 21st Century, Pp: 30 - 55, ISBN Number: 978 - 81 - 922746 - 9 - 0, S B Patil Institute of Management, Pune University, 18 -19 Jan 2019, Pune, India (National).
2. Satpathy, J. and Hejmadi, A. (2019).Cognitophysiological Drivers of Chaos in Business entrepreneurship Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) (Poster), CognitoPsychos Conference, Code: P - 05, CognitoPsychos Conference, 06 - 07 June, LUISS University, Rome, Italy (International).
3. Satpathy, J. and Hejmadi, A.(2020). Cognito - Smidgeons In Choosing To Decide (Poster), Proceedings of CognitoPsychos Conference, Serial: P - 08, 11 - 12 June 2020, University of Amsterdam, Amsterdam, Netherlands (International).
4. Satpathy, J. and Hejmadi, A.,Subhashree P. and Mishra, S. (2018). Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) Monikers in Business entrepreneurship Eyes, Proceedings of International Conference on Contemporary Issues in Business Innovation, Technology and Social Sciences, Gautam Buddha University, 01 - 02 June 2018, June 2018, Noida (UP), India (International).
5. Satpathy, J. and Mallik, B. (2018). Hematological Judgement in Business entrepreneurship Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s), Proceedings of International Conference on Management, Sciences, Engineering and Applications (ICMSEA - 2018), Dept. of Mathematics, Centurion University, Odisha; Kaziranga University, Assam and University of Perpetual Help, Philippines, 20 - 22 Dec 2018, Vishakhapatnam, India (International).
6. Satpathy, J. and Mallik, B. (2018). Hematological Judgement in Business entrepreneurship Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s), International Journal of Management, Technology and Engineering, ISSN No: 2249-7455, Volume 8, Issue XII, Pp: 2849 - 2863, December, India (International).
7. Satpathy, J. and Mallik, B. (2020). Computational ‘Cognito - Trajectories’ in Resolution, National Seminar on Mathematical Analysis and Computing (ACOMS 2020) and Proceedings of the 47th Conference of Odisha Mathematical Society, Dept. of Mathematics, National Institute of Science and Technology (Autonomous), Berhampur, 15 - 16 Feb 2020, Odisha, India (National).
8. Satpathy, J. and Mishra, D. P. (2019). Oculo - Empirical Signatures in Lending Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s, A Journal of Composition Theory (JCT), UGC - CARE Group ‘A’ Journal Approval Number: 18482, Volume XII, Issue VIII, August, Pp: 352-376, [DOI: 19.18001.AJCT.2019.V12I7.19.10048,](http://jctjournal.com/gallery/49-july2019.pdf) Karnataka, India (National).
9. Satpathy, J. and Mishra,S. (2018). Cognitive Competence ‘Agent’ in Organisational Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s, Proceedings of National Conference on Business Transformation Through Strategy And Innovation (BTTSI-2018), BIITM Institute, Biju Patnaik University of Technology, 11 July 2018, Bhubaneswar (Odisha), India (National).
10. Satpathy, J. and Neena, P. C. (2020). Cognito - Trajectories in Business entrepreneurship11O6ptimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s, Proceedings of the

National Conference on Application of Analytics in Business Reengineering, 07 March 2020, Christ University, Lavasa, Pune, Maharashtra. India (National).

1. Satpathy, J., Das, A. and Panda, M. and Gankar, S. (2020). Cognito - Cursors in Business entrepreneurship ‘Optimum preference neurofeedback Mosaic’, Journal of JuniKhyat, UGC - CARE Group I Journal, ISSN: 2278 - 4632, Volume 10, Issue 5 (14), Pp: 383 - 391, India (National).

**ANOVA**

1. Satpathy, J., Das, A., Laza, S. and Hejmadi, A. (2020). Experiment in Cognitobusiness entrepreneurship ‘Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)’, Journal of JuniKhyat, UGC - CARE Group I Journal, ISSN: 2278 - 4632, Volume 10, Issue 5 (6), Pp: 86 - 99, India (National).
2. Satpathy, J., Gankar, S. and Patnaik, J. (2020). Cognito - Couplings in Business entrepreneurship Optimum preference neurofeedback Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s), IUJ Journal of Management (IUJJOM), ISSN: 2347 - 5080, EOI: 10.11224 / IUJ, Volume 8, Issue. 1, Pp: 79 - 91, June, ICFAI University Jharkhand, India (National).
3. Satpathy, J., Hejmadi, A. and Gankar, S. (2020). Ophthalmological Catalysts in Business entrepreneurship Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) (Poster), Proceedings of CognitoPsychos Conference, Serial: P - 09, 11 - 12 June 2020, University of Amsterdam, Amsterdam, Netherlands (International).
4. Satpathy, J., Hejmadi, A. and Mishra, I. (2019).Clinical Observation On Cognito - Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) Capability, European Journal of Business and Social Sciences, ISSN: 2235-767X, Volume 07, Issue 05, May, Pp: 1091 - 1109, Zurich, Switzerland (International).
5. Satpathy, J., Hejmadi, A. and Padmaja, B. (2019), Cardio - Peep Into Organisational Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) Foundation, Proceedings of National Seminar on 'Human Dimension In Information Age', 21 - 22 Feb 2019, Acharya Nagarjuna University, Ongole, Andhra Pradesh, India (National).
6. Satpathy, J., Hejmadi, A., Laza, S. and Mishra, S. (2020). Cognito - Smidgeons in Deciding To Decide, Proceedings of National Conference on Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) Science and Operation Management: Recent Trends and Development, Birla Global University (BGU), Bhubaneswar, 07 March 2020, Odisha, India (National).
7. Satpathy, J., Hejmadi, A., Mishra, D. and Singh, S. (2018). Business entrepreneurship Eyes for Business Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s, FMU Journal of Management, Department of Business Management, Vol. 5 and 6, March 2018, Balasore, India (National).
8. Satpathy, J., Hejmadi, A., Singh, A. and Laza, S. (2020). Cognito - Genetic Underpinnings in Business entrepreneurship Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s), Thesis presented at the International Conference on Transforming HR in the Digital ERA: Prospects and Implicit Issues (INCTHR 2020), Institute of Management Studies, Ghaziabad, 11 Jan 2020, Ghaziabad, India (International).
9. Satpathy, J., Maheshkar, S. and Dharwadkar, K. (2019). Inquiry into Digitalised Cognito - Resolution, Proceedings of International Conference on Industry 4.0: Engaging with Disruptions, 30 Sep - 01 Oct 2019, Global Business School and Research Centre, Dr D Y Patil University, Pune, India (International).
10. Satpathy, J., Maheshkar, S. and Laza, S. (2019). Cognito - Evidence Grounded Business entrepreneurship Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s, Journal of Science, Technology and Development, ISSN: 0950-0707, UGC - CARE Group ‘A’ Journal, Volume. VIII, Issue. IX, September, Pp: 357 - 374, India (National).

117

1. Satpathy, J., Malhotra, S., Hejmadi, A., Pradhan, S., Sahoo, K. and Wadhwa, C. (2019). Endoscopic View of Cognito - Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s) Connectionism, European Journal of Business and Social Sciences, ISSN: 2235-767X, Volume 07, Issue 06, June, Pp: 182 - 202, Zurich, Switzerland (International).

**ANOVA**

1. Satpathy, J., Mallik B. and Garg, S., Hejmadi, A. and Gankar, S. (2019). Skin Conductance in ‘Smart’ Business entrepreneurship Judgement, Proceedings of 4thInternational Conference on Management, Sciences, Engineering and Applications (ICMSEA - 2019), Centurion University, Odisha; Kaziranga University, Assam and University of Perpetual Help, Philippines, 19 - 21 Dec 2019, Vishakhapatnam, India (International).
2. Satpathy, J., Mallik, B. and Garg, S., Hejmadi, A. and Gankar, S. (2020). Skin Conductance in ‘Smart’ Business entrepreneurship Judgement, Journal of Test Engineering and Management, ISSN: 0193

- 4120, Volume 83, Pp: 17581 - 17588, Mar - Apr 2020, The Mattingley Publishing Co., Inc., California, (USA) (International).

1. Satpathy, J., Pati, P., Hejmadi, A., Gankar, S. and Malhotra, S. (2019).Visual Monikers in Business entrepreneurship Optimum preference neurofeedbacks, ITIHAS: The Journal of Indian Management, July

- September Issue, ISSN Number - 2249-7803 (P), ISSN Number - 2456-7302, Page 51 - 55, India (National).

1. Satpathy, J., Pati, P., Hejmadi, A., Gankar, S. and Malhotra, S. (2019). Visual Monikers in Business entrepreneurship Optimum preference neurofeedbacks, European Journal of Business and Social Sciences, ISSN: 2235-767X, Volume 07, Issue 05, May, Pp: 374 - 380, Zurich, Switzerland (International).
2. Satpathy, J., Wadhwa, C., Rodriguez, C. M., Hejmadi, A. and Laza, S. (2020). Cognito - Curvatures in Business Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s, Proceedings of International Conference on Business, Information Technology and Enterprise Architecture, ICBIT - 2020, 25 - 26 September 2020, Management Development Institute

,Murshidabad, India (International).

1. Satpathy, J., Wadhwa, C., Rodriguez, C. M., Hejmadi, A. and Laza, S. (2020). Cognito - Curvatures in Business Optimum preference neurofeedback and substitutes grounded preference neurofeedback(s)s (Poster), Proceedings of CognitoPsychos Conference, Serial: P - 10, 11 - 12 June, University of Amsterdam, Amsterdam, Netherlands (International).